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EVALUATION OF UPPER MOTOR NEURON PATHOLOGY IN AMYOTROPHIC 
LATERAL SCLEROSIS BY MRI: TOWARDS IDENTIFYING NONINVASIVE 
BIOMARKERS OF THE DISEASE 
 
 
VENKATESWARAN RAJAGOPALAN 
 
ABSTRACT 
 
Amyotrophic lateral sclerosis (ALS) is the commonest adult motor neuron disease 
(MND) which causes progressive muscle paralysis and death usually within 5 years of 
symptom onset. As a result, only ~30,000 individuals in the United States are afflicted at 
any one time even though 5,000 or more individuals are diagnosed yearly. The diagnosis 
of ALS requires evidence of degeneration in upper motor neurons (UMNs) in the brain 
and in lower motor neurons (LMNs) that exit the brainstem and spinal cord to innervate 
skeletal muscles. Diagnosis can be incorrect or delayed when disease is early or atypical 
because non-invasive objective tests of UMN involvement do not exist, unlike 
electromyography to assess the LMN. Although magnetic resonance imaging (MRI) of 
brain and spinal cord is used primarily to identify conditions which mimic ALS, novel 
MRI sequences and post-processing techniques can identify macroscopic and even sub-
macroscopic changes in ALS brain related to neuronoaxonal degeneration (e.g., in 
corticospinal motor tracts). MRI-based techniques like diffusion tensor imaging (DTI) 
and proton magnetic resonance spectroscopy (1H-MRS), as well as nuclear medicine 
modalities like positron emission tomography (PET) and single photon emission 
vii 
tomography (SPECT) are being used to study brains of patients with ALS. Many previous 
MRI studies of ALS brain are limited either in methodology or information obtained 
being primarily qualitative, i.e. changes visible to the naked eye (macroscopic). This 
study employed both routine and novel MRI sequences to objectively assess gray and 
white matter pathology of the brain in ALS patients, including T2 relaxometry, DTI, and 
voxel based morphometry (VBM) of 3D high resolution T1-weighted images. DTI 
metrics showed significant (p<0.05) changes in rostral extent of corticospinal tract (CST) 
in ALS patients with predominantly UMN symptoms and signs, and the ALS-dementia 
patients, whereas more caudal involvement was observed in ALS patients with classic 
findings of UMN and LMN dysfunction. Significant (p<0.05) grey matter volume and 
cortical thickness reductions were observed only in the ALS dementia group when 
compared to controls, which suggests that neurodegeneration might begin as a 
neuronopathy in these patients. Preserved grey matter volume and cortical thickness in 
other ALS patients suggests a dying back axonopathy and warrants further study. To our 
knowledge this is the first study in a large number of ALS patients categorized into 
different subgroups based on their clinical presentation. Future comparisons of brain MRI 
and post-mortem histopathology in the same patient will allow radiopathologic 
correlation of tissue pathology underlying the radiographic changes, including CST 
hyperintensity. These may reveal differences in pathogenic mechanisms causing ALS 
which could respond differently to novel pharmacotherapies. 
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CHAPTER I 
 
INTRODUCTION TO AMYOTROPHIC LATERAL 
SCLEROSIS 
 
 
1.1 Amyotrophic Lateral Sclerosis (ALS) 
 
According to the National Institute of Neurological Disorders and Stroke (at the 
NIH) at least 30,000 Americans1 are afflicted with ALS and approximately 5,000 new 
cases are diagnosed annually. The term ALS is derived from ‘amyotrophic’ refering to 
muscle atrophy or weakness which signifies disease of the lower motor neuron (LMN) 
and ‘lateral sclerosis’ refering to scarring or gliosis of the lateral columns of the spinal 
cord, which indicates degeneration of the corticospinal tract portion of the upper motor 
neuron (UMN) 2. ALS is the commonest adult motor neuron disease (MND) that causes 
progressive degeneration of UMNs, which arise in the cerebral cortex 3 and of LMNs, 
which arise in the brainstem and spinal cord. This results in weakness, atrophy and 
spasticity of skeletal muscles involved in limb movement, speech, swallowing, and 
breathing. The disease is sporadic in ~90% of cases and familial in ~10% 2, 3. ALS affects 
individuals of all races in all geographic areas equally except for some minor exceptions 
like in Western Pacific where the prevalence is 50 times higher than elsewhere 2, 3. The 
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peak age of onset is between 50 and 70 years, with increasing age being the most 
important risk factor for developing ALS. In addition, patients developing ALS younger 
than 41 years tend to survive longer than those with onset older than 60 years 3. Males are 
affected 1.5 to 2.0 times more often than females, although this reaches unity (1:1) over 
65 years of age 3. Average survival after the onset of ALS symptoms is ~3 years with 
mean disease duration reported to be between 31 and 43 months3. The cause of ALS and 
its site of origin within the nervous system are unknown and it is universally fatal.  
 
1.2 Diagnosis 
 
ALS is relatively easy to diagnose when advanced or its fully developed classic 
form with combined UMN and LMN dysfunction, although there are exceptions to this 4. 
Diagnosis of ALS may be difficult and even be missed a) when atypical features occur, b) 
during certain stages of the disease when UMN or LMN features predominate, c) because 
a number of diseases can mimic ALS, including multiple sclerosis, radiculomyelopathy, 
multifocal motor neuropathy with conduction block, myasthenia gravis, and myopathy3, 
and d) because no single test definitively diagnoses ALS, and diseases that mimic it need 
to be excluded. 
 
All this results in diagnostic errors with some reporting only approximately 60% 
of ALS patients to be diagnosed correctly on their initial evaluation3. At present, 
diagnosis is based on consistent clinical features, evidence of disease progression, and 
laboratory investigations (e.g., blood tests, electromyography, and neuroimaging) 
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excluding conditions which resemble or mimic ALS, as mentioned above 5. As a result, 
the delay between symptom onset and definitive diagnosis of ALS averages 12 months. 
Considering 80% of patients survive only 3-5 years from onset of symptoms 2, shortening 
the time to diagnosis is imperative. There is great interest in identifying biomarkers of 
ALS which could allow earlier diagnosis, identification of disease subtypes (which exist 
phenotypically) and monitoring of disease progression to assess efficacy of 
pharmacotherapies.  
  
Based on the World Federation of Neurology El Escorial criteria 6, ALS is 
diagnosed only when there is evidence of both UMN and LMN dysfunction in the 
absence of other mimicking pathologies. This may be complicated in earlier stages or 
atypical forms of disease when UMN or LMN changes predominate rather than both 
motor neuron pools showing clinical dysfunction. Electromyography (EMG) provides an 
objective measure of LMN involvement even when it is not obvious clinically, but no 
equivalent exists for assessment of UMN dysfunction 7, 8. On the other hand, prominent 
LMN changes like muscle atrophy, hypotonia, and hyporeflexia can mask coexistent 
UMN signs arising from degeneration of cortical motor neurons and their projections. 
Novel applications of neuroimaging as a noninvasive objective measure of UMN 
involvement could assist in such diagnosis as well as provide insights into disease 
pathogenesis and progression.  
 
Presently, neuroimaging of brain and spinal cord of patients evaluated for ALS is 
used primarily to exclude pathologies that can mimic disease, such as strokes, tumors, 
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inflammation, demyelination, and compression 3. Conventional magnetic resonance 
imaging (cMRI) is the commonest imaging modality used for these purposes now. 
Special MRI applications like diffusion tensor imaging (DTI), proton magnetic resonance 
spectroscopy (1H-MRS), and nuclear medicine techniques like positron emission 
tomography (PET) and single photon emission tomography (SPECT) are increasingly 
being used to identify changes potentially specific to ALS 3, 9.  
1.3 Neuroanatomy 
 
For technical reasons, the UMNs in the brain are most accessible to MRI 
techniques that may reveal changes specific to ALS. A general understanding of the 
neuronal regions and tracts commonly affected in ALS is necessary to analyze and 
interpret the MRI changes.  
 
Cortical UMNs which project to lower brainstem spinal cord LMNs are localized 
primarily in layer V of the precentral gyrus (Broca’s area 4). The axons of all 
corticomotoneurons descend through the subcortical white matter through the corona 
radiata and centrum semiovale in a somatotopic orientation before entering the internal 
capsule and brainstem. Motor axons arising from cortical neurons in the far lateral 
hemisphere that travel within the corticobulbar tract, pass through the genu of the internal 
capsule to finally terminate on motor nuclei in dorsal regions of the midbrain, pons or 
medulla. In contrast, axons arising from more parasagittally located corticomotoneurons 
and traveling in the corticospinal tract (CST) pass through the posterior limb of the 
internal capsule to enter the brainstem. These CST fibers subsequently pass sequentially 
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through the cerebral peduncle of the midbrain, basis pontis, and finally pyramidal tract of 
the medulla prior to decussating at the cervicomedullary junction of the upper cervical 
spinal cord 3. Pictorial representations of corticobulbar and corticospinal tracts are shown 
in Figures 1 and 2. Both of these central motor axon tracts degenerate in ALS to varying 
degrees depending on the distribution of disease.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Pictorial diagram of Corticobulbar tract. 
 
Medulla 
Pons 
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Figure 2: Pictorial diagram of corticospinal tract. 
Motor cortex 
Pyramidal decussation 
Lateral CST 
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Typical clinical features when UMNs of the corticobulbar pathway degenerate 
include slurring of speech (dysarthria), swallowing difficulty (dysphagia), facial 
weakness, and spasticity (increased jaw jerk, facial reflexes, hyperactive gag), as well as 
pseudobulbar affect (pathologic laughter and crying). When corticospinal pathway 
UMNs are affected, typical clinical features include limb spasticity causing loss of finger 
dexterity and gait instability, limb and trunk weakness, and pathologically increased 
stretch reflexes 3.  
 
1.4 Neuroimaging in ALS 
 
Among the different neuroimaging modalities available today, MRI is preferred 
because it is noninvasive and can provide different contrasts between tissues types 
depending on the sequences used. This allows detection of abnormalities in ALS that are 
not detected by other modalities such as computed tomography (CT) 3. Continued 
improvements in MRI hardware (e.g. higher field strength magnets) and development of 
novel sequences and post-processing techniques have resulted not only in life-like images 
but also means to quantify abnormalities of structure and function. Examples of novel 
MRI techniques being used to identify structural and even functional brain pathology in 
ALS include diffusion tensor imaging (DTI)10 and functional MRI (fMRI)11 developed in 
the 1990’s. 
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1.5 Project Aim 
 
The etiology of ALS and its site of origin within the central nervous system (CNS) 
are unknown. By definition, the diagnosis of ALS is based on identifying motor neuron 
degeneration in both the CNS and peripheral nervous system (PNS), which can also be 
termed the upper motor neuron (UMN) and lower motor neuron (LMN), respectively. 
However, whether ALS neurodegeneration begins in the CNS or PNS is debated. In 
reference to a CNS (or UMN) origin, where degeneration begins is also unknown. 
Theoretically, it can begin anywhere along the rostrocaudal extent of the motor neuron 
pathway: in the motor neuron cell body (perikaryon) located in the cerebral cortex gray 
matter, as a neuronopathy, or along the motor axon in the subcortical white matter, as an 
axonopathy as shown in figure 3 below. If ALS is a neuronopathy, degeneration will 
proceed in an anterograde (proximal to distal or rostral to caudal) fashion with axon 
pathways affected later; if it is an axonopathy, degeneration will be retrograde (distal to 
proximal or caudal to rostral) with the perikaryon affected later. Based on preliminary 
data, the author hypothesizes that classic and UMN–predominant ALS is predominantly a 
dying back axonopathy with retrograde degeneration of the perikaryon. This is in contrast 
to patients with ALS and frontotemporal dementia (FTD) in whom the author 
hypothesizes neurodegeneration to begin in the neocortex (as a neuronopathy) with 
anterograde degeneration of the UMN. By testing these hypotheses, this study aims to 
identify biomarkers of the disease process which may help in making early diagnoses and 
provide insights into pathogenic mechanisms.   
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Figure 3: Schematic of neuronopathy and axonopathy locations in a neuron 
 
 
Even though ALS patients have clinical evidence of both UMN and LMN 
dysfunction, a large percentage of patients begin with UMN abnormalities and 
subsequently develop LMN signs. It is observed that some patients with predominantly 
UMN signs have bilateral CST hyperintensities visible on routine T2, proton density, and 
FLAIR images, while others do not, even though both groups have comparable degrees 
of clinical UMN dysfunction and duration of disease. The explanation for this difference 
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Myelin 
Dendrites 
Origin if 
neuronopathy 
Origin if 
axonapathy 
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in the presence or absence of CST hyperintensities is unknown. It is hypothesized that in 
UMN-predominant ALS patients without CST hyperintensities, the UMN degeneration is: 
(1) below the threshold of detection by routine MRI but still predominantly axonal, (2) 
arising in the cerebral cortex (as a neuronopathy) or (3) arising extracranially in the spinal 
cord (as an axonopathy). 
The above paragraphs suggests that pathological mechanisms of ALS may be 
different in ALS patients with predominant UMN signs with and without CST 
hyperintensity and  those of classic ALS and ALS with dementia. For instance clinical 
signs indicate more caudal onset of neurodegeneration (e.g. spinal cord) in classic ALS 
patients when compared with UMN predominant or in ALS dementia patients.  In order 
to gain better insight into the pathophysiological mechanisms of ALS disease process it is 
imperative to categorize ALS patients. Therefore in this study ALS patients were 
categorized based on their clinical symptoms and clinical evaluation of their conventional 
MR images; 1) ALS patients with predominant UMN signs when compared to LMN 
signs (based on their clinical evaluation) and in addition showed  hyperintense signal 
along CST (based on their conventional T2 and PD  weighted images), 2) ALS patients 
with predominant UMN signs when compared to LMN signs (based on their clinical 
evaluation) without any  hyperintense signal along the CST (based on their conventional 
T2 and PD  weighted images), 3) ALS patients with classic features i.e. no predominance 
in either UMN and LMN signs (based on their clinical evaluation) and 4) ALS patients 
with dementia (based on their clinical evaluation, conventional MR images and PET 
scan).  
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As shown in figure 4 below, T2 relaxometry and diffusion tensor imaging (DTI) 
will be used to interrogate axonal integrity within the corticospinal tract (CST), the major 
descending white matter motor tract and T1 imaging to examine volume (using voxel 
based morphometry, VBM) and thickness of the cerebral cortex as measures of neuronal 
integrity. These results will be compared to ALS patients with typical combined UMN 
and LMN signs, ALS patients with FTD, and neurologic control patients without ALS or 
UMN deficits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: MR imaging techniques to investigate axonal and neuronal   
 integrity in ALS 
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 Chapter II discusses quantitative T2 relaxometry technique employed in 
investigating axonal integrity within CST in UMN predominant ALS patients with and 
without CST hyperintensity. 
 
In Chapter III a novel non invasive modality called diffusion tensor imaging 
based on anisotropic diffusion property of water molecule in various neuronal fiber tracts 
was employed to investigate axonal integrity of CST in ALS patients. The main 
advantage of this technique over other conventional quantitative techniques is its ability 
to discern different neuronal fiber tracts within WM structures which otherwise appear 
homogeneous (conventional T1 or T2 weighted images).   Diffusion tensor metrics was 
used to determine whether the presence or absence of CST hyperintensities in UMN-
predominant ALS patients results from (1) divergent pathologies in subcortical axons (if both 
groups show similar changes) or (2) degeneration of the perikaryon in motor cortex or 
extracranial CST (if differences are found between groups). These results were then 
compared to ALS patients with typical combined UMN and LMN signs, ALS patients with 
FTD, and neurologic control patients without ALS. 
 
Chapter IV discusses assessment of neuronal integrity in ALS patients using high 
resolution T1 weighted images. Quantitative measurements techniques such as voxel based 
morphometry and cortical thickness were employed to assess grey matter volume changes in 
ALS dementia patients for evidence of cortical atrophy. These results were then compared 
with ALS patients with typical (combined UMN and LMN signs), ALS patients with 
predominant UMN signs and neurologic control patients without ALS. 
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CHAPTER II 
T2 RELAXOMETRY IN ALS 
 
2.1 Introduction 
 
Routine MRI studies using T2 weighted (T2-w), proton-density, and fluid 
attenuated inversion recovery (FLAIR) weighted images occasionally identify 
hyperintense signal along the CST 1 in a ALS patient as shown in Figure 5. 
 
 
 
 
 
 
 
Figure 5: Routine MR imaging, T2-weighted axial (left) and sagittal (right) 
MR brain images show corticospinal tract hyperintensity (arrows) in a UMN-
predominant ALS patient 
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Previous studies1 have demonstrated this change in 17% to 67% (median 40%) of 
ALS patients although a preliminary analysis at the Cleveland Clinic found this change in 
~31% of ALS patients. Based on one radiologic-pathologic study, such hyperintensity 
represents demyelination and wallerian degeneration of the descending CST fibers2. Such 
CST hyperintensity occurs in some but not all patients with very prominent UMN 
findings3 . 
 
Most previous MRI studies of ALS brain have described qualitative changes i.e. 
relying on visual evaluation of disease related abnormalities4. Such qualitative evaluation 
depends greatly on several factors, including: quality of the MR image (e.g. signal to 
noise ratio, SNR), limits of visual detectability, the interpreter’s experience and image 
reproducibility. These limitations can be minimized if the MR images can be 
quantitatively assessed. Some such quantitative MR image sequences which are currently 
employed in diagnosis of neurological diseases are magnetization transfer ratio (MTR), 
T2 relaxometry, DTI and T1-w volumetric imaging. The first study will focus on T2 
relaxometry as quantitative measures of ALS brain pathology.  
 
The premise of T2 relaxometry is the quantitative comparison of T2 relaxation 
times obtained from tissues which have different densities either normally (e.g., gray 
matter vs white matter) or because of pathology (e.g. motor fibers either healthy or 
undergoing wallerian degeneration). The basis of proton-based MR imaging is, in 
sequential order, the alignment of body protons (1H) in a static magnetic field (B0), the 
perturbation of this alignment by the application of a radiofrequency (RF) pulse 
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perpendicular to the direction of B0, the excitation of protons whose frequencies are in 
resonance with the RF field, and the return to steady state (equilibrium) of the protons by 
emission of this acquired energy. Body protons transfer this energy in two ways: (1) spin 
lattice relaxation when energy is emitted to their neighboring lattice due to mechanical 
motion and vibration; (2) spin-spin interaction when energy is transferred between 
closely adjacent protons. This latter process is known as T2 relaxation. In solids, where 
protons are more tightly packed and spin-spin relaxation is increased, T2 time will be 
short. In contrast, in liquids where protons are farther apart and spin-spin relaxation is 
decreased, T2 time will be long5 . Differences in T2 relaxation times may reflect 
structural changes arising from disease; for example, edema results in a prolonged T2 
relaxation time as more fluid accumulates. 
 
Previous studies6, 7 of T2 relaxometry in ALS used dual echo sequences because 
of clinical scanning time constraints and protocol simplicity. However, dual echo 
sequences are limited by inadequate sampling of the T2 decay curve8 , dependency on  
echo sampling intervals9, 10, poor signal to noise ratio8, 11 . Many T2 relaxometry studies12, 
13
 have employed fast spin echo (FSE) dual-echo sequence to measure T2 relaxation 
times. However, FSE sequence is prone to high spatial frequency effects. High spatial 
frequency effects occurs due to contrast averaging i.e. only the echo corresponding to 
effective TEs forms the center of the k-space, and the remaining echoes in the turbo 
factor or echo train length occupy other slabs of the k-space, resulting in a T2 contrast 
that will have some dependence on spatial frequency13. The concern here was that the use 
of data from a dual echo FSE sequence to measure T2 via the typical monoexponential fit 
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method would not accurately measure T2 relaxation time in all brain regions i.e. the 
signal in regions of high spatial frequency will correspond to a temporal evolution 
different than the “effective” echo time used in the fit. Thus, some error will occur 
depending on the spatial frequency characteristics of the brain region of interest. On the 
other hand, for a SE sequence, all signal is measured at approximately the same time and 
there will be no spatial frequency-dependence. The multiple-echo SE sequence will more 
properly measure T2 relaxation time in all regions regardless of spatial characteristics. 
 
2.2 Aim 
 
The aim of this study is to evaluate the accuracy of T2 relaxation times along the CST 
and whole brain white and grey matter structures derived from dual-echo FSE sequences 
relative to multiple-echo SE sequences. If the error values along CST are found to be 
within acceptable limits (< 10%) then T2 relaxation values measured using the dual-echo 
FSE sequence will be used to evaluate pathophysiology of ALS. 
 
2.3 Hypothesis 
 
It is hypothesized that errors of T2 relaxation times based on dual echo FSE sequence 
would be large in high spatial frequency regions (i.e. at brain structure edges), but small 
in low spatial frequency regions such as the CST.  
If the above hypothesis is true, then T2 values from dual echo FSE sequence will be 
used to investigate the following hypotheses. It is hypothesized that in UMN-
predominant ALS patients without CST hyperintensities, UMN degeneration is either: (1) 
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below the threshold of detection by routine MRI but still predominantly axonal, (2) 
arising in the cerebral cortex (as a neuronopathy) or (3) arising extracranially in the spinal 
cord (as an axonopathy). 
2.4 Methods 
 
2.4.1 Image sequences 
 
Clinically obtained MRI data and storage of de-identified images was approved by 
our local Institutional Review Board as part of the “Neuroimaging Registry/Database for 
CNS Analysis in Patients with Motor Neuron Disease”. Both dual-echo FSE and 
multiple-echo SE images were acquired axially in 9 subjects (8 ALS patients and 1 
control) aged 49 to 84 (63±11.7, mean±SD) years on a 1.5 T MRI scanner (Siemens 
Symphony, Erlangen, Germany). Dual-echo FSE imaging parameters were: number of 
slices = 40, contiguous, slice thickness = 4 mm, in-plane resolution = 0.9×0.9 mm; pulse 
sequence parameters were: TR = 3900 ms, TE = 26 ms and 104 ms, echo train length or 
turbo factor = 7, and number of averages = 1; total scan time = 3.5 minutes. Multiple-
echo spin echo imaging parameters were: number of echoes =16, number of slices = 8, 
covering the upper half of the brain, slice thickness = 4 mm, slice gap = 4 mm, in-plane 
resolution = 1.3×0.9 mm; pulse sequence parameters were: TR = 3900 ms, 16 TEs 
ranging from 22-352 ms, number of averages = 1; total scan time = 7.5 minutes. A high 
resolution 3D T1-w MPRAGE sequence provided good grey-white matter contrast 14. 
MPRAGE imaging parameters were: number of slices = 160, contiguous, slice thickness 
= 1 mm, in-plane resolution = 0.9×0.9 mm; pulse sequence parameters were: TR = 1970 
ms, TE = 4.38 ms, number of averages = 1, flip angle =10o, TI =1100 ms and scan time = 
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6.45 minutes. DTI was also performed using EPI sequence along 12 diffusion weighted 
(b = 1000 s/mm2) directions and one b0 = 0 s/mm2 for identification of CST. Imaging 
parameters were: 30 slices, 4 mm thick, with 1.9×1.9 mm in-plane resolution; pulse 
sequence parameters were: TR = 6000 ms, TE = 121 ms, EPI factor = 128, number of 
averages = 6 and scan time = 7.54 minutes. Because EPI-based DTI data is geometrically 
distorted by susceptibility artifact at bone-air-tissue interfaces, gradient-echo sequence 
field map images were acquired. Field map imaging parameters were: number of slices = 
30, slice thickness = 4 mm, slice gap = 4 mm, TR=500 msec, TEs = 6.11 and 10.87 msec. 
 
2.4.2 Data processing 
 
Relaxation of signal intensity after a spin echo pulse sequence is given by equation 
15.  
Signal (S) 
……..…………………………….1 
Where M0 is proton density, T1 and T2 are longitudinal and transverse relaxation 
times.TR timing was set long enough in the imaging protocol to exclude T1 effects14 . T2 
relaxation times are then estimated by assuming a mono exponential decay model which 
is as given in equations 2 below.  
………………………………………………… 2 
S0 being a parameter of no interest, the images are then log transformed and the final 
equation which is used to calculate T2 map is given in equation 3 below. 
..………………………………………………. 3 
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TE2 and TE1 are the echo timings, and S1 and S2 are the image signal intensities at the two 
echo time points, respectively. 
Using the above equation, T2 relaxation times are calculated for every voxel resulting in 
a T2 map. Since only mono-exponential fit is possible with the FSE sequence the SE data 
were fitted with the same mono-exponential model. All SE images were linearized by log 
transformation and a linear least square fit was used to estimate the T2 decay curve using 
all sixteen echos.  A percentage error map was then calculated from the T2 maps obtained 
from SE and FSE sequences, as given in equation 4 below.     
  
……………..…..…….4 
 
2.4.3 Regional T2 relaxation values  
Two approaches were taken to validate T2 relaxation times derived from FSE 
sequences compared to SE sequences. The first was to assess error values of T2 
relaxation times along the CST in ALS patients. DTI was used to generate tractography 
maps identifying exact location of each patient’s CST. The second was to assess T2 
relaxation time error across whole brain GM and WM structures.  
2.4.3.1 CST T2 relaxation time error values 
 
T2 relaxation time error values were calculated along the CST in the following 
manner:  (a) CSTs are reconstructed from the patient’s own DTI images after correction 
of field distortion by using FUGUE from FSL (http://www.fmrib.ox.ac.uk/fsl/)15, 16. (b) 
Undistorted DTI images are processed using DTI Studio open software 
(https://www.mristudio.org/)17) to estimate diffusion tensor matrix for each element in the 
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voxel is calculated based on multivariate linear least square fit, and the obtained tensor 
matrix is diagonalized to derive eigenvalues and eigenvectors. (c) Virtual neuronal fibers 
are reconstructed using the fiber assignment by continuous tracking (FACT) algorithm 17, 
which is described in detail elsewhere18. The tracking parameters used were: termination 
FA threshold value = 0.2 21 and bending angle threshold = 41o.  
 
After these preliminary processing steps, CST fiber tracts were reconstructed after 
Wakana et al19  by placing one region of interest (ROI) caudally in the cerebral peduncle 
and another rostrally just below the primary motor cortex. Subsequently, a map of CST 
tracts was obtained and DTI images were registered to T2-w images by co-registering 
b=0
 
images with T2-w images using an affine transformation (FLIRT from FSL)20. 
Finally, the transformation matrix was applied to the CST tracts and a CST mask image 
was created in order to superimpose them over the calculated error maps as shown in 
figure. 6. Compared to manually tracing the ROI, we found that this tractography-based 
method gives more accurate identification of the CST, is highly reproducible as it is free 
of operator bias, and is less time intensive. T2 relaxation error values (percentage error as 
given in equation 4) were obtained along the intracranial CST, percentage error values 
were plotted as histograms for left and right CST separately as shown in figures 7) and 8) 
and  the mode values of the peak of the histograms were measured as error value in each 
and every subject and are given in Table I 
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Figure 6: CST tracts superimposed on T2 relaxation map in  one of our ALS 
 patients 
 
 
CST Left CST Right 
CST Left CST Right 
Coronal slice view 
Axial slice view 
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Figure 7: Histogram of  absolute percentage error values along left CST in 
 one of our subjects 
 
 
 
 
 
 
 
 
 
 
Figure 8: Histogram of absolute percentage error values along right CST in  
one of our subjects 
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2.4.3.2 Whole brain T2 relaxation time error values 
 
All image processing was done with FSL open software 
(http://www.fmrib.ox.ac.uk/fsl/)16. GM and WM segmentation was performed on T1-w 
MPRAGE images because they provide good grey-white contrast. T2 relaxation time 
error maps were calculated from whole brain WM and GM structures in the following 
manner: (a) Brain and non-brain structures were extracted using BET21, and the extracted 
brain image was segmented into WM, GM and CSF probability maps using FAST22 . (b) 
Affine registration was used to register T1-w images to T2-w images using FLIRT20, 23 . 
(c) The transformation matrix was then applied to WM and GM maps. (d) A binary mask 
of WM and GM was created by setting a threshold value of P> 0.75 to eliminate any 
misclassified WM, GM or CSF tissues. (e) WM and GM masks were then multiplied with 
the percentage error map to obtain whole brain GM and WM error values as shown in 
figure 9 a) and b). Processing steps from a) to d) was pictorially represented in figure 10 
below. Error values of T2 relaxation times in GM and WM structures were then plotted as 
histograms. Figure 11 a) and b) shows typical histogram of WM and GM error values  in 
one of our subjects .Mode values of the peak of the histograms were measured as error 
value in each and every subject and are given in Table II.. 
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Figure 9: MR images of Grey matter a)and White matter b) absolute  
percentage error maps in one of our subjects 
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Figure 10: Pictorial representation of processing steps for whole brain 
 approach 
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Figure 11: Histogram of whole brain absolute percentage error values of a)  
white matter b) grey matter structures in one of our subjects 
a) 
b) 
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2.5 Results 
 
T2 relaxation value errors calculated from FSE vs. SE sequences in all 9 brains 
are shown for the CST (Table I), and for whole brain WM and GM structures (Table II). 
In the CST, error values were >10% in all subjects and >20% in 6 of 9 subjects (Table I). 
This was surprising since we had initially hypothesized that T2 relaxation value errors in 
the CST would not be high (>10%) since this region should normally not have high 
spatial frequency characteristics. Large errors would be expected only in brain regions 
with high spatial frequency because FSE sequences have pronounced high spatial 
frequency effects. On the other hand, whole brain GM and WM regions generally had 
low error values (<10%), although 6 subjects had error values slightly >10% in WM 
regions (Table II). Overall, WM and GM T2 relaxation values were similar between FSE 
and SE derived sequences suggesting a greater proportion of low vs. high spatial 
frequency regions in whole brain. Also unexpected was the lowest percent error occurring 
in the GM fraction considering the cortical surface would be expected to exert high 
spatial frequency effects. 
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Table I: Mode values of absolute percentage error in T2 Relaxation Times  
along Right and Left Corticospinal Tracts measured from histogram in all  
the subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   SD- Standard deviation 
 
 
 
 
Mode values of 
absolute percentage error 
Subject 
Left  CST Right  CST 
1 15.56 19.67 
2 18.16 19.14 
3 26.53 18.55 
4 21.55 22.53 
5 22.58 18.51 
6 23.5 24.63 
7 23.64 9.58 
8 18.84 23.76 
9 30.63 20.02 
Mean 22.33 19.59 
SD 4.55 4.39 
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Table II: Mode values of absolute percentage error in T2 Relaxation  
Times in whole brain gray and white matter structures measured from  
histogram in all the subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  SD- Standard deviation 
2.6 Discussion 
 
T2 relaxometry studies in ALS by Hofmann et al.6,  and Tanabe et al.,7 used a 
dual-echo SE sequence to measure relaxation times along the CST of patients and control 
% Error Subject 
WM GM 
1 12.5 4.5 
2 15.5 2.5 
3 12.5 1.5 
4 16.5 3.5 
5 2.5 3.5 
6 8.5 1.5 
7 8.5 47.5 
8 13.5 2.5 
9 16.5 38.5 
Mean 11.83 11.72 
SD 4.60 17.90 
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subjects but failed to detect significant differences between groups. Reasons for this may 
include small sample size 7, manual ROI identification of the CST region 6, 7 and different 
MR sequence parameters such as TEs 30 ms and 100 ms 6 vs. 20 ms and 80 ms 7. Another 
reason may be the inherent error caused by dual-echo sequences in measuring T2 
relaxation time, as demonstrated in an earlier single slice study by Whittall et al.10 They 
found that T2 values were underestimated with a dual-echo sequence using a 
monoexponential fit when compared to a 32-echo CPMG sequence using 
multiexponential fit, which produced more accurate relaxation times10. Even though 32-
echo single slice studies are considered to be the gold standard for accuracy of T2 
relaxation times, limiting measurements to a single slice because of time constraints may 
miss important information as ALS pathology may be located in other regions.  
 
Duncan et al 9 showed that dual-echo FSE sequences are less accurate when 
compared to dual-echo SE sequences. The large error in T2 relaxation values derived 
from FSE sequences along the CST brings into question the validity of results in studies 
using this technique. This is even more important when longitudinal measures are 
performed because the significance of changes detected over time may not be valid. 
Especially in diseases like ALS, it is imperative to have a robust measure of T2 relaxation 
times where longitudinal studies are vital not only to study effects of disease progression 
but also to assess the effects of potential disease modifying agents. 
 
Undoubtedly, the main drawback to obtaining multiple-echo SE sequences is the 
increased scanning time; in our study, acquiring 16 echoes over 8 slices (with 4 mm slice 
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gap) took 8 minutes whereas acquiring 40 contiguous slices with a FSE sequence took 
only 3.5 minutes. In clinical scanning protocols, this is a major consideration since other 
sequences are also acquired, such as MPRAGE images and DTI, as in our study. The 
patient’s ability to remain motionless in the scanner is also limited, especially when 
dementia or other co-morbidities exist. This may be the reason why many T2 relaxometry 
studies of patients with Huntington’s disease 13, epilepsy 12, 24, and multiple sclerosis25  
have used FSE sequences. The increasing use of ultra-high field strength magnets (e.g., 
3T and higher) and the development of novel scanning sequences will likely overcome 
the time limitations of multi-echo sequences.  
 
Finally, the Carr-Purcell-Meiboom-Gill (CPMG) sequence is generally accepted 
as a more accurate way to measure T2 with MRI. Future work should include the use of 
the CPMG sequence to understand issues related to in vivo T2 measurements for clinical 
studies. 
 
2.7 Conclusion 
 
The results clearly demonstrates that T2 relaxation times obtained using dual-echo 
FSE sequences are not as accurate as values estimated from data acquired using multiple-
echo SE sequences. Therefore, T2 relaxometry based on dual-echo FSE sequence will not 
be used further to investigate the changes in ALS patients. Based on above findings it is 
recommended that future T2 relaxometry studies employ multi-echo SE sequences or 
CPMG for accurate and reliable results.  
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2.8 Limitations and Future Scope 
 
The percentage error estimation method adopted in this study may raise concerns 
about the level of acceptable error i.e. ~10%. To overcome the above the drawback 
student t-test map can be obtained in order to determine significant difference between 
the T2 relaxation maps of dual echo FSE and multiple echo SE sequences.  
Low percentage error values seen in whole brain grey matter structures suggest 
that T2 relaxation time measured using dual echo FSE sequence can be used to 
investigate changes in grey matter structures. Future studies can be directed along this 
line. 
 
In the next chapter our second study using novel non invasive modality called 
diffusion tensor imaging (based on anisotropic diffusion property of water molecule in 
various neuronal fiber tracts) was employed to investigate axonal integrity of CST in 
ALS patients. The main advantage of this technique over other conventional quantitative 
techniques is its ability to discern different neuronal fiber tracts within WM structures 
which otherwise appear homogeneous in conventional MR images (e.g. T1 or T2 
weighted images). Diffusion tensor metrics was used to evaluate pathophysiological 
changes in ALS patients when compared to controls. 
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CHAPTER III 
 
DIFFUSION TENSOR IMAGING IN ALS 
 
3.1 Introduction 
 
Onset of a disease is accompanied by pathologic changes initially at the 
microscopic level, before becoming evident macroscopically. Detecting such changes as 
early as possible is best for purposes of diagnosis and treatment of any disease process. 
Unlike other conventional MR techniques, diffusion tensor imaging (DTI) is based on 
diffusion of water molecules at the microscopic level. DTI’s efficacy and power in 
providing this microscopic information non-invasively enabled clinicians and researchers 
to study ALS along the line of multiple sclerosis1, 2  and other motor neuron disease 
(MNDs)3, 4. As mentioned in section 1.5 of chapter 1, DTI is an appropriate tool to study 
axonopathy in MNDs.  
 
DTI is a relatively recently described modality based on the freedom with which 
water molecules (protons) move randomly within tissue5 . Because DTI is based on this 
microscopic level event, it is unique among MR modalities and has the potential of 
 39 
detecting tissue pathology at near sub-macroscopic levels. Identifying tissue pathology by 
MRI before it has progressed significantly has several advantages, including more timely 
diagnosis and earlier therapeutic intervention. In a progressive neurodegenerative disease 
like ALS, DTI may non-invasively detect pathologic changes which are still at or near 
microscopic levels. In addition, because most nerve fiber tracts are compact bundles of 
myelinated motor axons oriented in parallel (e.g., CST or ascending tracts), their DTI 
characteristics will be different whether healthy (intact) or undergoing degeneration 
(disrupted).  
 
Highly coherent structures like axon bundles do not allow protons (of water 
molecules) to diffuse freely in all directions, isotropically. Rather, they restrict protons to 
move primarily in one direction (along their length), anisotropically; densely packed fiber 
bundles therefore normally possess high anisotropy and their disruption results in 
decreased anisotropy. By measuring the magnitude of proton diffusion in multiple 
directions, fiber (and tract) orientation can be determined6.  However, in order to 
determine directionality of highly convoluted or irregular fiber tracts without scanning in 
an excessive number of directions, a tensor model based on a limited number of diffusion 
direction measurements was developed6.  This is the origin of the term diffusion tensor 
imaging (DTI) and figure 12 below shows how diffusion information is encoded in the 
tensor matrix.  
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Figure 12: Representation of water diffusion becoming anisotropic in the  
presence of compact tissues and how that information is encoded in diffusion 
 tensor matrix. 
 
The diffusion tensor matrix obtained from diffusion data contains both scalar and 
vectorial measures. Scalar diffusion measures, i.e., fractional anisotropy (FA) and mean 
diffusivity (MD), are widely employed because they are vector invariant (independent of 
the direction of measurement) and provide quantitative information7.  The most widely 
evaluated scalar parameters in ALS are MD and FA given in equations 1 and 2 below. FA 
represents the amount of anisotropy in the diffusion tensor 8 which is increased by fiber 
tract coherence and integrity and reduced by demyelination or degeneration. MD 
represents proton diffusion within one or more voxels (region)8  which decreases as water 
molecules are more restricted in movement.  
 
…………………………………………………….(1) 
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  ..............................................................................(2) 
 
 
Conventional MRI and DTI produce significantly different images, as shown in 
figure 13 below. In conventional T1-w MRI, white and gray matter is visually 
distinguishable because of contrast differences but white matter myelin appears mostly 
homogeneous (Fig. 13a). In DTI, the directionality of fiber orientation in white matter 
produces contrast differences and provides additional tract information (Fig. 13b) 6 . An 
elegant extension of DTI is tractography, in which fiber tracts can be reconstructed in 
three dimensions based on vector information from the tensor matrix (Fig. 13c).  
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Figure 13: Brain MRI of one of our ALS subjects showing: a) T1 weighted 
image, b) DTI FA color map based on vector information (i) red color for left-right 
orientation, (ii) green for antero-posterior direction and (iii) blue for rostrocaudal 
orientation; and c)CST neuronal tracts reconstructed based on DTI tractography 
 
As can be seen from the previous paragraphs that DTI images are not only more 
informative when compared to conventional MRI scans but also have the ability to detect 
microscopic changes occurring at very early stages of the disease process. This will 
a) b) 
c) 
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enable the detection of pathologic changes at a much earlier stage and potentially before 
the disease advances to an irreversible state. Furthermore, the tractography feature of DTI 
will enable not only reconstruction of virtual neuronal fiber tracts which are affected by 
the disease process but also identification of newer fiber tracts which might be prone to 
ALS degeneration.  
 
Previous DTI studies in ALS employed two different approaches in assessing fiber 
tract integrity: ROI-based and voxel-based morphometry (VBM). The ROI-based 
approach is hypothesis directed and is best suited when there is a priori knowledge about 
regions that are affected by the disease process. On the other hand, the VBM based 
approach assumes no prior knowledge about the regions affected by the disease process 
and is therefore an exploratory one.  
 
3.1.1 ROI-based approach 
 
Many DTI studies in ALS have used ROI based identification of the CST at various 
levels to compare FA and MD values between patients and control subjects. Most of these 
studies revealed reduced FA and increased MD in the posterior limb of the internal 
capsule in ALS patients compared to controls7-10. Hong et al11  used trace information 
(which is the sum of diagonal elements of the eigen values of the DTI matrix) to 
overcome errors introduced by partial volume effects when manually tracing CST in the 
medullary pyramids. On the other hand, Schimrigk et al10 used a probability mixture 
model which would overcome some but not all drawbacks of the ROI based approach. 
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The advantage of this model is that it is independent of the resolution of the data and by 
dividing the voxels within the ROI into a) pure fibers class, b) pure background class and 
c) a partial volume class of both fiber and background class reduces not only partial 
volume effects but also interobserver differences. Nonetheless, ROI based approaches 
which require manual identification of brain regions which are labor intensive, are prone 
to poor inter- and intrarater reproducibility, and generate partial volume effects. 
 
3.1.2 VBM-based approach 
 
Voxel-based morphometry (VBM) analysis allows objective and automated 
detection of structural differences in brain tissue (e.g. atrophy) between subjects after 
normalizing for random shape differences12. Being an unbiased assessment, it can be used 
for exploratory analyses when no a priori knowledge of distribution in pathology is 
available. For example, atrophy in ALS may occur outside of motor regions, especially 
when patients have additional dementia, making VBM-based morphometry an ideal 
approach to studying this. Once the patient’s brain is fitted to a common brain template 
(e.g., from normal controls) which normalizes for any random variation between brains 
shapes and sizes, it is smoothed and a statistical parametric map generated of grey and 
white matter from which significant differences in tissue amounts is identified between 
patient and control brain templates.  
 
A VBM-based approach has been applied to DTI measures. Sach et al13  and 
Thivard et al14 generated statistical parametric maps of FA values and found reductions 
not only in CST and pyramidal tracts but also in the thalamus, corpus callosum and in 
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other extramotor regions of ALS brains when compared to controls. In contrast, Abe et 
al15  found changes only in the CST and pyramidal tracts. The disparate results may be 
due to different patient phenotypes with varying degrees of involvement in non-motor 
brain regions supporting the notion that ALS is a multisystem disease16. 
 
Since our DTI data has large slice thickness contributing significantly to partial 
volume effects and anisotropic voxels leading to poor signal to noise ratio (SNR), VBM 
based approach will not be followed in this study. 
 
3.1.3 Fiber Tractography 
 
Virtual fiber tracts can be generated in 3D from quantitative DTI information (fiber 
tractography) providing a visual correlate to the data. Abe et al15  first employed 
tractography in ALS to accurately localize the supratentorial CST. In their more extensive 
study, Wang et al17 used color maps and fiber tracking in ALS to show a thinning of the 
CST in ALS compared to control brain. They also showed a reduction in CST fiber 
number in ALS patients compared to control individuals. Although mean CST volumes in 
right and left hemispheres were not different between affected and unaffected 
hemispheres, the total CST volume in both hemispheres was significantly lower in ALS 
patients compared to healthy volunteers.  
 
Fiber tractography is sensitive to angular threshold, vector step length, and seed ROI; 
it also shows variability among subjects because of anatomical differences. 
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3.2 Limitations of current ALS DTI studies  
 
Some of the limitations of the above mentioned studies are: a) manual ROI 
identification, b) Changes in FA values can result from either decrease in axial diffusivity 
or increase in radial diffusivity or could be due to both18. It is also demonstrated using an 
example that even if a patient and a control subject have same FA values their individual 
axial and radial diffusivities may vary greatly18. FA (equation 2) being calculated taking 
into account all the eigen values cannot show differences when one or more eigen values 
increase or decrease. In other words, FA can differentiate neither radial (
2
32 λλλ +=⊥ ) & 
axial ( 1λλ =ll ) diffusivity figure 14, nor the tubular ( λ1 > λ2 ≈ λ3) & planar anisotropy 
( λ1 ≈ λ2 > λ3) as shown in figure 15 below.  
 
 
 
 
 
 
 
 
 
Figure 14: Axial and radial anisotropies Lambda 1 (λ1) being along the fiber 
called as axial anisotropy and λ2 & λ3 being perpendicular to fiber orientation so 
their average named as radial anisotropy 
 
λ1 
λ2 
λ3 
 47 
 
 
 
 
 
 
 
 
 
Figure 15: Ilustration of  Tubular anisotropy ( λ1 > λ2 ≈ λ3 )  A)and planar 
anisotropy ( λ1 ≈ λ2 > λ3) B). (where green and blue colors indicate different fiber 
populations)  
 
 
So in order to overcome the above drawbacks we propose to study radial and axial 
diffusivities, and Westin’s CP = (λ2- λ3)/λ1 and CL = (λ1- λ2)/λ1 for tubular and planar 
anisotropy 19, 20. As can be seen from the above definitions CL will be bright for tubular 
regions and dark for planar regions and CP on the other hand will be bright for planar 
regions and dark for tubular regions. 
 
Other important issues that will be addressed in this work are: a) categorizing 
ALS patients into various subgroups and b) evaluating susceptibility artifacts in CST. 
Many DTI studies in ALS failed to categorize/classify ALS patients appropriately based 
A) B) 
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on their clinical symptoms thereby leading to inconclusive results7, 17. Since ALS patients 
manifest themselves with variable clinical symptoms (like predominant UMN, classic 
ALS, or predominant LMN symptoms) it is imperative to categorize them according to 
their clinical symptoms rather than pooling them under a single category of “ALS”. 
Motivation to categorize ALS patients came from the observance of hyperintense signal 
along CST in T2-weighted images in some but not all of the ALS patients with 
predominant UMN signs21, 22. It is intriguing to know whether there is any difference in 
DTI metrics between UMN predominant ALS patients with and without hyperintensity 
along CST. We believe that categorization will enable us to better understand the 
pathophysiological mechanisms of ALS, for instance DTI measures will be used to 
determine whether the presence or absence of CST hyperintensities in UMN-predominant 
ALS patients results from (1) divergent pathologies in subcortical axons (if both groups 
show similar changes) or (2) degeneration of the perikaryon in motor cortex or 
extracranial CST (if differences are found between groups). Therefore, ALS patients were 
categorized into four different groups namely; a) predominant UMN ALS with 
hyperintense signal along CST (observed in their T2-weighted images), b) predominant 
UMN ALS without CST hyperintensity, c) ALS patients with mixed UMN and LMN 
signs (classic ALS), and d) ALS patients with frontotemporal dementia (FTD).  
 
Most of the DTI studies in ALS employed single shot echo planar imaging (SS-EPI) 
sequence7, 9, 10, 13, 15, 23-25. SS-EPI suffers greatly from susceptibility artifacts at air-tissue-
bone interfaces. Since most of the clinical DTI protocols are inherently devoid of field 
map acquisition scan we aimed to investigate the effects of susceptibility artifacts along 
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CST.  
 
3.3 Aim 
 
The goal of this study is to evaluate pathology in ALS using scalar DTI metrics like 
fractional anisotropy (FA) along the CST. We also aimed to explore the usefulness of 
indices namely; radial and axial anisotropy, Westin’s CP and CL, which are yet to be 
studied in ALS. 
 
3.4 Hypothesis 
 
It is hypothesized that a) DTI metrics (FA, RA,  MD, radial and axial diffusivities) 
will be significantly different in the CST among ALS subgroups and  between ALS and 
control groups. b) If there is no difference in DTI metrics between CST hyperintense and 
non-hyperintense groups then there are divergent pathologies in subcortical axons. c) In 
classic ALS with mixed UMN and LMN findings, disease onset is more caudal when 
compared to UMN predominant ALS patients. d)  CST will not be significantly affected 
by susceptibility artifacts. 
 
3.5 Method 
 
3.5.1 DTI Protocol 
 
Clinically obtained MRI data and storage of de-identified images was approved by 
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the Institutional Review Board at the Cleveland Clinic as part of the “Neuroimaging 
Registry/Database for CNS Analysis in Patients with Motor Neuron Disease”.  DTI data 
of 8 control subjects (5 men, 3 women), 13 UMN predominant with CST hyperintensity 
ALS patients (C-group) (8 men, 5 women), 21 UMN predominant without CST 
hyperintensity ALS patients (B-group) (15 men, 6 women), 12 ALS patients with 
predominant LMN signs  (E-group) (9 men, 3 women) and 14 ALS patients with 
dementia (D-group) (3 men, 11 women) was obtained using 1.5 T system (Siemens 
Symphony, Erlangen, Germany). DTI was performed using echo planar imaging (EPI) 
sequence along 12 diffusion weighted (b = 1000 s/mm2) directions and one b0 = 0 s/mm2. 
Imaging parameters were: 30 slices, 4 mm thick, with 1.9×1.9 mm in-plane resolution; 
pulse sequence parameters were: TR = 6000 ms, TE = 121 ms, EPI factor = 128, number 
of averages = 6 and scan time = 7.54 minutes. Gradient-echo field map images were 
acquired to correct for geometrical distortion caused by susceptibility artifacts. Field map 
imaging parameters were: number of slices = 30, slice thickness = 4 mm, slice gap = 4 
mm, TR=500 msec, TEs = 6.11 and 10.87 msec.  
 
3.5.2 Data processing 
 
DTI images were first corrected for distortion effects using FSL’s FUGUE 
(http://www.fmrib.ox.ac.uk/fsl/)26-28. Undistorted DTI images were then processed using 
DTI Studio open software (https://www.mristudio.org/)29.. DTI matrix for each voxel was 
calculated based on multivariate linear least square fit. The tensor matrix was then 
diagonalized to derive principal eigen values and eigen vectors. Maps of diffusion metrics 
namely Fractional anisotropy (FA), relative anisotropy (RA), mean diffusivity (MD), 
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parallel diffusivity (λ||) radial diffusivity ( ⊥λ ), Westin’s linear (CL) and planar (CP) 
index were obtained. Virtual neuronal fibers were reconstructed using the fiber 
assignment by continuous tracking (FACT) algorithm29 , described in detail elsewhere. 
Fiber tracking parameters were initiated from every voxel with FA = 032, threshold for 
termination was 0.232 and a bending angle of 41o.  
 
After these preliminary processing steps, all subjects CST fiber tracts on both left 
and right sides were reconstructed after Wakana et al32 by placing first ROI caudally in 
the cerebral peduncle (CP) and the second rostrally just below the primary motor cortex. 
Along the CST, four regions of interest (ROIs) were identified to evaluate the 
pathophysiological changes in ALS. These are cerebral peduncle (CP), internal capsule 
(IC), top of the lateral ventricle (LV) and subcortical motor cortex (MC). DTI metrics 
mentioned above were measured for each subject in these ROIs and were compared 
against controls and also between the patient subgroups. We randomly selected 19 of 68 
subjects to study distortion effects caused by susceptibility artifacts along the CST. In 
these 19 subjects diffusion tensor matrix and the diffusion metrics were calculated for 
both conditions i.e. with and without field map corrections. ROIs of same size and shape 
were applied at CP and MC levels while reconstructing the CST in both with and without 
field map corrected images. The number of CST fibers, CST fiber volume and average 
FA along the entire CST were evaluated to determine the effects of susceptibility artifacts.  
Statistical comparisons for each of the DTI metrics across control and patient groups 
were carried out using SPSS 16.0. Based on data meeting the assumptions of ANOVA 
one of the following statistical methods was used with a significance level of p < 0.05; a) 
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one-way ANOVA followed by Tukey’s post hoc test was carried out when the 
assumptions of both normality and equal variance were met.  b) On the other hand only if 
the equal variance assumption was violated Welch ANOVA followed by Dunnett T3 post 
hoc test was employed.  c) When both normality and equal variance assumptions were 
violated Kruskal-Wallis non-parametric approach followed by Bonferroni correction of 
Mann-Whitney test was used. The effects of susceptibility artifacts was evaluated by 
employing Student T-test or Mann-Whitney U test based on data meeting the assumptions 
of normality and equal variance.  
 
3.6 Results 
 
The statistical group comparison results along different levels of CST for FA, RA, MD, 
axial and radial diffusivities are given in Figures 16 to 20. 
 
3.6.1 Fractional anisotropy 
 
FA values were found to be reduced in all ALS groups when compared with the 
controls. FA values showed significant difference between control and the CST 
hyperintense, CST non-hyperintense and dementia groups at the level of IC. In addition 
to this, the ALS-dementia and CST hyperintense groups were significantly different from 
controls on the left CP. On the other hand FA values were significantly different between 
control and classic ALS groups only at the level of CP. Dementia patients were 
significantly different from the controls in CP and IC levels. Besides this, there was no 
significant difference among the ALS sub groups at any levels of the CST.  
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3.6.2 Relative anisotropy 
 
Similar to FA results, RA values were found to be decreased in ALS patients when 
compared to controls. RA results were similar to FA values except that there was no 
significant difference between control and CST hyperintense and dementia groups on the 
left CP.  
3.6.3 Axial and Radial diffusivities 
 
In general, axial diffusivity values were reduced in ALS patients compared to 
controls. Axial diffusivity, on the other hand, showed significant differences between 
control and CST hyperintense, CST non-hyperintense and classic ALS groups mainly in 
the left IC; however with CST non-hyperintense group, the difference was significant on 
the right side too. Between ALS subgroups, axial diffusivity was significantly different 
between CST non-hyperintense group and dementia group at the level of IC. On the other 
hand, between classic ALS and ALS-dementia groups, significance was observed only in 
the right MC. Radial diffusivity values, on the other hand, were elevated in ALS patients 
compared to controls, and were almost identical to FA values at the IC level; at the CP 
level, radial diffusivity also reached significance between CST non-hyperintense and 
classic ALS groups.  In addition, radial diffusivity was significantly different between 
control and ALS groups in the left LV, i.e. CST hyperintense and CST non-hyperintense, 
whereas significant differences were observed in both right and left LV levels between 
control and dementia patients.  
 
3.6.4 Mean diffusivity 
 
In general, MD values were elevated in ALS patients when compared to controls. 
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MD was significantly different between control and CST hyperintense and ALS-dementia 
groups in the left IC; the ALS-dementia group also showed significance at the LV level. 
Between ALS groups, comparisons resulted in significant differences between dementia 
and CST hyperintense, CST non-hyperintense and classic ALS groups in the right LV. In 
addition to this, the ALS-dementia group was also significantly different from CST non-
hyperintense and classic ALS groups in the left IC.    
3.6.5 Susceptibility artifact measures 
 
Total number of CST fibers, fiber volume and average FA values along the entire 
CST were measured in order to evaluate susceptibility artifacts. These results are given in 
Table 3. No significant difference (p>0.05) was observed in any of the above measures 
obtained with or without field map correction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
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Figure 16: FA results at various levels of CST a) Right CST and b)Left  CST.  
revealing significant difference between groups at p<0.05 
 
b) Where CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical 
motor cortex.  
 
Significance at p<0.05 
b) 
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a) 
b) 
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Figure 17: RA results at various levels of CST a) Right CST and b)Left  CST  
revealing significant difference between groups at p<0.05 
 
 
Where  CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical 
motor cortex.  
 
Significance at p<0.05 
a) 
 58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: MD results at various levels of CST a) Right CST and b)Left  CST  
revealing significant difference between groups at p<0.05 
 
 
Where   CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical 
motor cortex.  
 
Significance at p<0.05 
b) 
 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
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Figure 19: Axial diffusivity results at various levels of CST a) Right CST  
and b)Left  CST revealing significant difference between groups at p<0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
Where   CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical 
motor cortex.  
 
Significance at p<0.05 
a) 
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Figure 20: Radial diffusivity results at various levels of CST a) Right CST  
and b)Left  CST revealing significant difference between groups at p<0.05 
 
 
 
 
 
 
 
 
Where   CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical 
motor cortex.  
 
Significance at p<0.05 
b) 
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3.7 Discussion 
 
3.7.1 Fractional anisotropy 
 
FA results seen in this study at the level of the IC agree well with previous ALS 
studies8-10, 13, 15, 33.  Absence of significant differences between CST hyperintense and 
non-hyperintense groups in all the DTI metrics suggests that divergent pathologies may 
exist in the extracranial (e.g.spinal cord) axons of these two groups rather than 
degeneration of the perikaryon in motor cortex or extracranial CST. One of the reasons 
we didn’t observe any significance at the MC level between CST hyperintense and non-
hyperintense groups might have resulted from the truncation of CST below MC in 7 of 13 
patients in the former group and 7 of 21 in the latter group. However, this was not 
observed in the ALS-dementia or in control subjects, however in the classic ALS 
group,only 2 of 12 subjects’ left CST tracts were truncated below the MC level. Since 
acquisition and post-processing of images in all groups were performed identically, we 
believe the extent of CST degeneration is greater in these patients than in the others. 
Figure 21 a) shows the CST in a control subject and figure 21 b) shows absence of CST 
in MC in a UMN predominant CST hyperintensity patient. Further studies are required in 
order to validate these findings. 
 
 
 
 
 
 63 
 
 
 
 
 
 
 
Figure 21: Sagittal view of FA color map shows localization of using subject’s  
own tractography-derived CST a) control b) UMN predominant  
hyperintense patient 
 
 
3.7.2 Relative anisotropy 
 
 Jacob et al33 observed reduction in RA values in the pyramidal tract in one UMN 
ALS patient before and after a 9 month follow-up, while no significant difference was 
reported in two patients with LMN and bulbar symptoms. In our study, RA values were 
significantly different between the classic ALS group and controls in the CP, whereas 
comparison between other ALS groups (CST hyperintense, non-hyperintense and 
dementia groups) and controls significance was reached only in the IC.  Since the study 
paradigms are different and a very small population of ALS patients was studied by Jacob 
et al33 the results are difficult to compare.  
 
 
a) b) 
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3.7.3 Axial and Radial diffusivities 
 
Christian Beaulieu18  showed that changes in FA values can result from either 
decreased axial diffusivity, increased radial diffusivity, or both. He also demonstrated that 
two subjects can have the same FA values but individual axial and radial diffusivity 
values may differ. Beaulieu18 also shows some encouraging evidence from animal and 
human studies suggesting that axial diffusivity physiologically corresponds to axonal 
degradation and radial diffusivity to myelin degradation. However, these interpretations 
should be interpreted with caution because they are likely over-simplifications and further 
studies are warranted to confirm these above findings. Nonetheless, The above factors 
suggest that a more accurate physiological insight can be obtained by using axial and 
radial diffusivities.  
 
Axial diffusivity values in our study reached significance only at the IC level 
between control and ALS groups whereas, Wong et al34 showed significant increase only 
in corona radiata. In our study, we observed a decreasing trend in axial diffusivity values 
from the CP to MC in both control and ALS patients. Discrepancies in these results may 
be due to the following factors: a) ALS group studied by Wong et al included both bulbar- 
and limb-onset patients, b)  small sample size (only 14 ALS subjects), c) less number of 
diffusion weighting directions in both studies (Wong et al  employed 6 directions, ours 12 
directions) whereas studies by Jones et al35 and Ni et al36 recommend 30 directions for 
robust estimation of individual eigen values λ1, λ2 and λ3,  d)  significant partial volume 
effects from thicker slices (Wong et al’s 5 mm thickness, ours 4 mm), e) compared to 
manual ROI tracing,  tractography methods result CST identification which is more 
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accurate, more reproducible37,  free from operator bias, and less time intensive. 
Tractography methods on the other hand are sensitive to signal to noise ratio, anatomical 
variability between subjects6 and resolution. An interesting finding in our study was that 
axial diffusivity revealed significant differences between the ALS subgroups which was 
not observed with FA or RA. Axial diffusivity values were significantly elevated in the 
ALS-dementia group at the IC level when compared with the CST hyperintense group, 
and at the right MC level when compared with classic ALS group.  
 
Radial diffusivity values revealed some variation in our ALS patients when 
compared to controls, being elevated in the MC, reduced in IC and increased in CP. On 
the other hand, Wong et al showed a decreasing trend rostrocaudally from the corona 
radiata to the CP. They failed to observe significant differences between ALS patients and 
control subjects whereas in our study radial diffusivity not only showed significant 
difference between these groups, but we also found it to be significantly elevated in the 
classic ALS group when compared with UMN predominant CST non-hyperintense group. 
An interesting point here is that radial diffusivity values between control and UMN 
predominant CST hyperintense, UMN predominant CST non-hyperintense and ALS-
dementia groups were not significantly different at CP level but were more rostrally, i.e. 
at IC and LV levels. In contrast, control and classic ALS groups showed significant radial 
diffusivity differences only at the CP level and not higher up along the CST. Values were 
significantly higher in the classic ALS group, when compared to UMN predominant CST 
non-hyperintense group suggesting a more pronounced CST degeneration in the classic 
ALS patients (who have prominent LMN degeneration) at the CP level when compared to 
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the UMN group. Diffusion metrics FA, RA also showed significant differences between 
control and classic ALS groups at the CP level but not rostrally along the CST. Taken 
together, our findings suggest that axon degeneration in classic ALS patients (who have 
prominent LMN signs) may be more caudal (e.g., at the spinal cord level) when 
compared with UMN group (who do not). To our knowledge, this is the first MRI study 
using tractography to evaluate axial and radial diffusivities along the CST in large 
subgroups of ALS patients.  
 
3.7.4  Mean diffusivity 
 
In general MD values in ALS patients were found to be elevated at all the levels 
of the CST when compared with controls. However, MD values reached significance 
more rostrally i.e. in LV and IC levels between control and ALS groups and also among 
ALS subgroups. Between group comparisons showed significant increases in MD values 
in the left IC of ALS-dementia patients when compared with classic ALS and UMN CST 
non-hyperintense groups. Our results at the IC level agree with other ALS studies7, 38, 39. 
However, Yin et al39  in their study group of ALS patients (6 limb onset , 2 bulbar onset) 
found no significant differences in MD values at IC.  
 
3.7.5 Westin’s linear (CL) index and planar index (CP) 
 
The values of DTI metrics along the CST at the LV level were found to be slightly 
different from those of the other 3 ROIs. In our control subjects, axial diffusivity values 
were lowest in LV region compared to those at CP, IC & MC levels, and radial diffusivity 
values were higher in LV region compared with other 3 ROIs. Since the LV ROI is in a 
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region where superior longitudinal fasciculus fibers cross with the CST, we explored this 
using Westin’s linear index (CL) and planar index (CP)19, 20. Westin’s index is a 
geometrical index which measures the shape of the diffusion tensor ellipsoid against 
scalar measures like FA. Westin’s CL (where λ1>>λ2≈ λ3) measures uniformity of tracts in 
a voxel whereas Westin’s CP (where λ1≈ λ2 >> λ3) indicates fiber crossings. If there is 
fiber crossing, the planar index (CP) will have high values (close to 1) whereas the linear 
index (CL) will be low (close to 0).  Table III gives Westin’s CL and CP (left and right 
side combined) for all the 4 ROIs in control subjects. Average linear values (CL) were 
found to be lower in LV region when compared with other 3 ROIs, on the other hand 
planar values were comparatively elevated in LV. Figure 22 a) and (b) shows changes in 
CL values at the level of cerebral peduncle and in LV. Figure 23 (a) and (b) are the color 
maps of CL at cerebral peduncle and LV obtained by using CL map and first eigen vector. 
High linear index and low planar values in CP and IC agree well with the anatomical 
structure of CST in these regions (i.e. highly coherent and uniform), so reduced linear 
index and slightly elevated planar index in LV indicates that there may be more than one 
fiber population in this region. 
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Table III: Average values of Westin’s linear and planar indices at different  
levels of CST 
 
 
 
 
 
 
 
 
 
CP-cerebral peduncle, IC-internal capsule, LV-top of lateral ventricle, MC-
subcortical motor cortex 
 
 
 
 
 
 
 
 
 
 
Figure 22: Transverse image of a control subject’s CL map a) Cerebral  
peduncle level, b) top of lateral ventricle level 
 
Westin’s Index CP IC LV MC 
Linear index (CL) 0.64 0.68 0.41 0.46 
Planar index (CP) 0.09 0.12 0.19 0.15 
a) b) 
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Figure 23: Transverse image of a control subject’s CL color map a) Cerebral  
peduncle level, b) top of lateral ventricle level 
 
 
3.7.6 Evaluating susceptibility artifacts in CST 
 
Figure 24 (a) and (b) shows DW images before and after field map correction. It 
can be seen from Table IV that parameters number of fibers, fiber volume and average FA 
values remain almost identical in CST between with and without field map correction 
procedures which suggests that CST is not affected by susceptibility artifacts. Under 
regular conditions, field maps were not acquired as part of clinical DTI protocols.  Since 
most of the clinical studies employ SS-EPI sequence we believe that susceptibility 
artifacts need to be corrected before employing these images for any research purpose 
because to our knowledge there are no post-processing techniques available today to 
correct for these distortions. However, the results of this study indicate that if CST is the 
primary region of interest then field map acquisitions may not be required. 
a) b)  
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 Table IV: Measures to evaluate susceptibility artifacts in CST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SD- standard deviation 
 
 
 
 
 
 
 
 
Number 
of fibers 
Fiber volume 
(number of 
voxels) 
FA Measure 
With 
field 
map 
Without 
field 
map 
With 
field 
map 
Witho
ut 
field 
map 
With 
field 
map 
With
out 
field 
map 
Mean±S
D 
48.82
±48.7
9 
42.58±4
6.44 
195.95
±160.4
2 
183.36
±157.7
1 
0.50
2±0.
05 
0.50
1±0.
05 
Median 34.5 23 
158.5 149.5 
0.49
7 .499 
Quartile
s      (1st, 
3rd) 
14,  
63.50 
12,  
63.50 
101.25
, 
230.25 
105.25
, 
191.75 
0.46
5 
0.53
0 
0.47
4,  
0.53
0 
Mann-
Whitney 
U test / 
T-test 
P=0.395 P=0.617 P=0.
963 
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Figure 24: Transverse image showing susceptibility artifacts in frontal 
regions of the brain a) before correction, b) after correction in one of our subjects 
 
 
In essence, the discrepancies seen in results between our study and the ALS literature 
can be due to some of the following factors; a) tractography method is sensitive to signal 
to noise ratio, anatomical variability between subjects and resolution. According to Mori6, 
tractography method gives 30% variability even when used within control subjects. b) On 
the other hand ROI approach suffers from operator bias, poor reproducibility and is time 
consuming. c) Studies35, 36 have shown that at least 30 directional measurements are 
required for robust estimation of eigen values whereas only 12 directional DTI data was 
acquired in our study (due to scanner software constraints). d) Thicker slices of 4 mm in 
our study will contribute of partial volume effects and anisotropic voxels may affect 
tractography results. 
 
a).  b).  
 72 
3.8 Conclusion 
 
One caveat is that comparing and contrasting results of this study with others may be 
inaccurate because of differences in used DWI schemes and sequences, number of 
gradient directions, and methods to process DTI images. However, similarities between 
results from this and previous DTI studies are changes in FA and MD values at the level 
of internal capsule in ALS patients compared to controls. This study shows that axial and 
radial diffusivities provide additional information when compared to anisotropy measures 
FA or RA. To our knowledge, this is the first study to assess diffusion metrics in a large 
group of ALS patients after being categorized into different subgroups, and to 
demonstrate that CST measures remain unaffected by susceptibility artifacts. This study 
also shows that subcategorizing ALS patients by clinical features (e.g., extent of UMN 
and LMN dysfunction) reveals group-specific differences in DTI metrics which suggests 
variance in ALS pathogenesis, increasingly considered a syndrome rather than a single 
disease. Finally, by showing that DTI measures along the CST are unaffected by 
susceptibility artifacts, additional field map correction sequences would not be necessary 
for clinical imaging protocols, thereby saving time and data storage space. However, 
future studies with larger sample sizes of subgroups and using robust DW acquisition 
schemes are warranted to confirm our findings. 
3.9 Limitations and Future scope 
 
The main limitation of this study is the low directional DTI data (12 directions), 
anisotropic voxels which result in suboptimal signal to noise ratio, and thicker slices 
contributing to partial volume effects. Future studies will utilize probabilistic tracking 
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instead of the deterministic approach (used in this study) to reconstruct the entire CST to 
assess the reason for its truncation rostrally in some ALS patient subgroups. This will 
reveal whether the truncation is due to differences in the disease process and provide 
novel insights into pathogensis. Adding more control subjects will increase the power of 
the statistical tests. Future comparisons of DTI and post-mortem histopathology in the 
same patient will allow radiopathologic correlation of tissue pathology underlying the 
radiographic changes, including CST hyperintensity. 
 
Next study addresses assessment of neuronal integrity in ALS patients using high 
resolution T1 weighted images . Quantitative measurements techniques such as voxel based 
morphometry and cortical thickness were used to assess grey matter volume changes  
especially in ALS patients when compared to controls. 
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CHAPTER IV 
Voxel Based Morphometry and Cortical Thickness in ALS 
 
 
4.1 Voxel Based Morphometry 
4.1.1 Introduction 
 
Although ALS has been traditionally regarded as purely a motor neuron disease, 
there is increasing awareness of extramotor involvement, especially of brain regions 
subserving cognition and behavior1. Unlike dementia in Alzheimer’s disease, the 
cognitive impairment seen in some patients with ALS affects predominantly 
frontotemporal areas and is known as frontotemporal dementia (FTD). A recent discovery 
that nuclear TDP-43 protein is mislocalized to the cytoplasm in patients with ALS, FTD, 
or both is the first pathobiologic link between these two conditions2. 
 
2,3-FDG positron emission tomography (PET) studies of ALS patients with co-
existent dementia have revealed reduced cerebral blood flow in frontotemporal regions 
which indicates neuronal hypometabolism, as shown in figure 25. When dementia is 
advanced, cerebral atrophy usually is detected on MRI.  
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In this study we aim to understand the extent of extramotor involvement in ALS 
patients by assessing the degree of atrophy in gray matter (GM) structures in different 
patient subgroups using 3D high resolution T1-w images.   
 
 
 
 
Figure 25: [18F]2-fluoro-2-deoxy-D-glucose PET brain imaging of an ALS  
dementia patient showing reduced metabolism in both temporal lobes 
 (arrowheads) and inferior frontal lobes (arrowheads). 
 
 
Conventional MRI of ALS patient brain usually shows little if any atrophy, 
although this is likely a misrepresentation because of the qualitative nature of these 
studies3. Quantitative assessment of high resolution 3D MR images will allow more 
precise measures of GM and white matter (WM) loss in ALS. Post mortem studies have 
revealed various forms of cortical pathology in ALS ranging from obvious neuronal loss 
to neuronal shrinkage but no loss or no obvious pathology, all in the setting of 
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proliferation and hypertrophy of neuroglia, which add to the complexity of the degrees of 
cortical atrophy in ALS.  
 
Voxel-based morphometry (VBM) analysis allows objective and automated 
detection of structural differences in brain tissue (e.g. atrophy) between subjects after 
normalizing for random shape differences4. Being an unbiased assessment, it can be used 
for exploratory analyses when no a priori knowledge of distribution in pathology is 
available. For example, atrophy in ALS may occur outside motor regions, especially 
when patients have additional dementia, making VBM-based morphometry an ideal 
approach to studying this. Once the patient’s brain is fitted to common brain template 
(e.g., study-specific template created from a sub-group of patients under study) which 
normalizes for any random variation between brains shapes and sizes, it is smoothed and 
a statistical parametric map generated of grey matter from which significant differences 
in tissue amounts are identified between patient and control brain templates.  
 
 Atrophy measures in ALS GM and WM throughout the brain will also assess the 
growing belief that ALS is a multisystem disease and not restricted to motor regions, 
even in patients without frontotemporal dementia (FTD)1, 5, 6. Ellis and colleagues were 
the first to apply VBM to ALS patient brains6. Their study using T2-weighted images 
showed significant differences in GM and WM volumes between ALS and control 
subjects and also between ALS with limb-onset and bulbar-onset groups. Using VBM, 
Chang and collaborators studied GM and WM changes in ALS patients with (n=10) and 
without (n=10) FTD when compared to control subjects (n=20)7. No WM volume 
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change was observed either between ALS subgroups or between ALS and controls 
subjects. Distribution of GM volume change was similar between ALS with and without 
FTD except that ALS-FTD patients had more atrophy in motor, premotor and frontal and 
posterior thalamus. Based on these observations, they concluded that a continuum of 
cortical atrophy exisits between these two ALS groups. Abrahams and colleagues studied 
GM and WM changes in ALS patients with and without cognitive impairment which was 
assessed based on verbal fluency test5. ALS patients with FTD were excluded from their 
study. ALS with cognitive impairment showed extensive atrophy changes in both motor 
and in extra- motor (frontal and temporal) WM structures when compared to both 
controls and unimpaired ALS patients. However, no significant change was observed in 
any of the GM structures. They also reported that the above changes were consistent with 
their PET studies suggesting that cognitive impairment may be more common in ALS 
patients and not restricted only to ALS patients with dementia. Mezzapesa and 
collaborators on the other hand, studied atrophy changes in 9 healthy and 16 ALS patients 
without any cognitive deficits8. VBM results showed significant (p<0.001, uncorrected) 
reductions in gray matter volume in temporal and frontal lobes of non-demented ALS 
patients compared to controls, although WM volume loss was not observed.  
 
4.1.2 Limitations of previous studies 
 
Large slice thickness (e.g., 3 mm in studies by Abrahams et al5 and Chang et al7) 
contributes to partial volume effects; voxel resolution of 1×1×1 mm is highly 
recommended for VBM studies7 . Absence of significant differences in clinical measures 
between ALS-FTD and ALS groups in the study by Chang and colleagues raises concerns 
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regarding criteria used to classify ALS patients into subgroups7. The study by Ellis and 
collaborators, on the other hand, employed T2-weighted images, which suffer from poor 
tissue contrast between GM and WM structures6. Inadequate information was provided 
by Abraham and colleagues regarding level of significance and multiple comparisons, 
making assessment of their methodology difficult5. In addition, Mezzapesa and 
collaborators identified p<0.001 but this was uncorrected for multiple comparisons8. This 
raises significant statistical concerns considering VBM tests the same hypothesis in every 
voxel and correcting for multiple comparisons is therefore mandatory. Furthermore, the 
aforementioned studies all employed Gaussian random field theory based statistical 
comparisons for which the analyzed data should have had Gaussian distribution. 
However, several studies9-11 have shown that these criteria are difficult to verify and meet 
due to inherent noise in the data and so recommend non-parametric permutation based 
analyses for statistical comparisons. Therefore, the discrepancies seen in the above 
studies can be attributed to various factors, including: methodological differences (e.g., 
imaging parameters, statistical analyses) and combining patients with differing clinical 
presentations and stages of disease, assuming that they all manifest the same disease. 
 
4.1.3 Aim 
 
Earlier studies provide ample evidence that ALS is a multifactorial entity (i.e. 
processes like neuronal degeneration, gliosis) causing effective changes in cerebral (e.g., 
GM and WM) volumes. Therefore, we aimed to measure changes in volume of GM 
structures due to atrophy in our ALS-FTD patients primarily, but also in our other ALS 
patient subgroups.  
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4.1.4 Hypothesis 
 
It is hypothesized that cerebral GM volume is significantly different between 
control individuals and ALS patients and also between the ALS subgroups themselves. 
We also hypothesize that if GM volume is lower in ALS patients compared to control 
subjects, onset of neurodegeneration in ALS is in the perikaryon (cell body), as a 
neuronopathy. If, on the other hand, no change is detected in cerebral GM volume of ALS 
patients compared to controls, the disease process is a “dying-back” (retrograde 
axonopathy) phenomenon. 
4.1.5 Method 
 
4.1.5.1 Imaging protocol 
 
Magnetization prepared rapid gradient echo (MPRAGE) sequence was used to 
acquire T1 weighted images on a 1.5 T system (Siemens Symphony, Erlangen, Germany) 
in 9 control subjects (6 men, 3 women), and 72 ALS patients: 13 UMN-predominant with 
CST hyperintensity (8 men, 5 women), 25 UMN-predominant without CST 
hyperintensity (16 men, 9 women), 14 typical ALS with mixed UMN and LMN signs (9 
men, 5 women), and 20 with ALS-FTD (5 men, 15 women,). This high resolution 3D T1-
weighted MPRAGE sequence provided good GM-WM contrast14. MPRAGE sequences 
are less sensitive to pulsation artifacts because of shorter TEs and saturation effects of 
flowing blood in the whole excitation volume11. The following MPRAGE parameters 
were used for pulse sequence: TR = 1970 ms, TE = 4.38 ms, number of averages = 1, flip 
angle =10o, TI =1100 ms, scan time = 6.45 minutes, and imaging: number of slices = 160, 
contiguous, slice thickness = 1 mm, in-plane resolution = 0.9×0.9 mm. 
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4.1.5.2 Data Processing 
 
An optimized VBM approach of Good and colleagues was adopted12 with all 
processing steps carried out using openware FSL (http://www.fmrib.ox.ac.uk/fsl/). Data 
processing was divided into four major steps: (1) Brain extraction in all the subjects using 
fsl_vbm_1_bet routine, with manual editing to remove any remaining non brain regions; 
brain extracted images were segmented into WM, GM and CSF probability maps. (2) 
Creation of a study specific GM template13 by registering a subset of subjects from 
control and ALS groups into the MNI152 space (to avoid bias during the registration 
process). 3) GM template was created were registration of all subjects to the study-
specific GM template using both linear and non-linear registration methods; GM volumes 
were concatenated and smoothed (to increase singal-to-noise ratio) using a Gaussian 
kernel of 3 mm with a full-width half-maximum (FWHM) of ~7 mm. (4) Application of 
permutation based non-parametric statistics to the data set to identify significant 
differences in GM volume between control subject and ALS groups. As mentioned above, 
non-parametric statistical approaches are recommended in the literature8-10 because the 
data often violates Gaussian distribution. A general linear model (GLM) was adopted to 
compare differences in GM volume between 4 different ALS subgroups and the control 
group. A p<0.05 corrected for multiple comparisons using false discovery rate (FDR) was 
considered the level of significance. 
4.1.6 Results 
 
Significant differences were detected in motor and extra motor regions only 
between control and ALS-FTD subjects, as shown in figure 26 below. Cortical regions 
significantly atrophic in ALS-FTD patients compared to controls are shown in figure 26 
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to be: frontal and temporal lobes, occipital fusiform gyrus, lingual gyrus, lateral occipital 
cortex inferior division, inferior temporal gyrus temporooccipital part, temporal occipital 
fusiform cortex, lateral occipital cortex superior division and superior parietal lobule. The 
extra motor regions of inferior temporal gyrus, fusiform gyrus, and lingual gyrus have 
cognitive functions30, including face recognition30, word recognition, and color 
information processing. The hippocampus in the temporal lobe is primarily responsible 
for long-term memory30. Non-motor frontal and prefrontal areas are responsible for 
executive functions, behavioral and emotional regulation. GM volume changes in ALS-
FTD supports our hypothesis that these patients exhibit early neurodegeneration in the 
perikaryon (as a neuronopathy) with early anterograde degeneration affecting the entire 
axon with wallerian degeneration . No other ALS subgroup showed GM volumes that 
were significantly different from control individuals, consistent with a “dying back” 
axonopathy of motor pathways and relative preservation of the perikaryon until later in 
the disease process. Like our findings, Sage et al13 and Abrahams et al5 also did not 
identify significant differences in GM volume between control subjects and ALS patients 
without dementia whereas other studies did7,8. Discrepancies in results between our study 
and the latter ALS studies may be due to the following: a) potential misclassification by 
Chang and collaborators7 of ALS patients with and without dementia considering both 
groups had similar clinical symptoms; b) use of uncorrected statistics (p<0.001) by 
Mezzapesa and colleagues8, which will lead to large Type I error; c) employment of 
Gaussian random field (GRF) theory based statistical analysis by both of these groups7,8, 
while we used a non-parametric permutation based approach.  
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Figure 26: Regions  which showed statistical significance between control and  
ALS dementia were shown by superimposing them on MNI brain template 
 
 
4.1.7 Conclusion 
 
Absence of GM changes in non-demented ALS patient subgroups supports our 
hypothesis that such patients may experience a “dying back”axonopathy of the UMN 
with only late perikaryon degeneration and loss. In contrast, GM loss in ALS-FTD 
patients suggests an early loss of perikaryon (neuronopathy) with resultant global 
anterograde wallerian degeneration. 
 
 
 88 
4.1.8 Limitations and Future Scope 
 
Since previously published ALS VBM studies widely employed GRF-based 
statistical analyses, a comparison of these and permutation based statistics in same 
sample of patients and controls would determine whether discrepancies between different 
studies are due to the statistical procedures utilized. A larger sample study, especially of 
the control group, would confirm our findings. 
A better understanding of the pathophysiological mechanisms in ALS can be 
achieved by combining GM VBM results with brain 2,3-FDG PET data in order to 
correlate structural and functional changes. In addition, combination of VBM and DTI 
studies would help validate the dying-back axonopathy vs. early neuronopathy sites of 
degeneration in ALS patient subgroups. Confirmation and validation of our findings 
could be achieved by post-mortem histopathological studies of such patients showing the 
aforementioned VBM changes. 
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4.2 Cortical Thickness in ALS 
 
4.2.1 Introduction 
 
The human cerebral cortex has a complex organization of layers and columns: a) 
six horizontal layers (I-VI) each having a unique cellular organization and synaptic 
connections, b) multiple vertical columns (comprised of neurons and surrounding 
neuropil) for each single function and c) subdivision of each column into hypercolumns, 
which combine different functional columns. Therefore, pathological changes of cortical 
neurons (e.g. shrinkage or loss) and surrounding neuropil resulting in physiologic 
dysfunction may affect column length (e.g. reduction), which in turn alters cortical 
thickness (e.g. reduction). Therefore, a physical and functional change in the cortical 
neuronal circuitry is reflected by altered cortical thickness (usually reduced). Thinning of 
the cortex due to pathological changes has been widely reported in various neurological 
disorders namely; Alzheimer’s disease15, Huntington’s disease16 and multiple sclerosis17. 
Voxel based morphometry (VBM) described in the previous section quantitatively 
assesses GM volume changes in the brain using high resolution T1-weighted images. 
However, VBM provides only part of the information because volume change can result 
either from changes in cortical thickness or cortical surface area or both and 
differentiating between the two is not possible with VBM. In addition, estimation of GM 
volume by VBM includes both cortical thickness and cortical foldings (gyri and sulci) 
such that adjacent gyri can be mistaken as a single GM area, as shown in figure 27, 
resulting in erroneous high GM concentration18. Cortical thickness measurements 
overcome this error, as well as providing additional information on the possible 
pathophysiological changes in ALS, as discussed above.  
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Figure 27: a) Cartoon of adjacent gyri appearing connected to each other, b) 
MR image in which this gyral foldings (adjacent gyri abutted) appears as a single 
large GM area (indicated by cross hair). 
 
 
An earlier study reported shrinkage in the surface area of precentral gyri of ALS 
patients although without significant differences between ALS and control subjects on 
group comparisons3. A stereological study surprisingly found no abnormalities in post 
mortem ALS brain tissue after estimating total number of cortical neurons, measuring 
cortical thickness, as well as surface area and volume of neocortex, white matter and 
central grey nuclei19. Measurements in the two aforementioned studies were performed 
manually which is not only time consuming but also introduces operator bias and poor 
reproducibility. Furthermore, huge errors in thickness measures will result if the image 
plane is not perpendicular to the cortical surface, as pointed out by Fischl and Dale20 .As 
shown in figure 28 below, measuring cortical thickness in the same location (identified by 
green dot) but in two different planes will result in a higher value in the coronal view as 
compared to axial view. This discrepancy occurs because cortical thickness is measured 
Adapted from Jason Lerch Master’s thesis proposal 
a) b) 
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parallel to the imaging plane in the coronal view but perpendicular to it in the axial view. 
In their earlier study, Kiernan and Hudson identified six potential measurement errors of 
cortical surface area by MRI: partial volume, head tilt, plane of view, contiguous slices, 
intensity manipulation, and magnetic inhomogeneities3. 
 
 
 
 
 
 
 
 
 
Figure 28: Cortical thickness of the same cortical region is over estimated 
when measured in the coronal plane (a) compared to the axial plane (b) where it is 
more accurately represented  
Adapted from Fischl, (2000). 
 
 
The aforementioned drawbacks of manual cortical thickness measurements can be 
essentially removed if automated image processing techniques are employed. Therefore, 
a fully automated cortical thickness measurement software (developed by Fischl and 
Green dots indicate the same 
cortical location but in two 
different planes demonstrating 
how thickness measures will be 
greater in the coronal view (a) 
than in the axial view (b). 
a) b) 
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Dale20) was used in this study to assess cortical thickness in our ALS patient subgroups. 
Multiple earlier studies have amply demonstrated that ALS is a multicellular 
disorder (i.e. neuronal shrinkage and/or loss, gliosis) causing degenerative changes in 
GM structures  
4.2.2 Aim 
 
Our VBM study showed significant GM volume loss in only ALS-FTD dementia 
patients but not in the other ALS subgroups, compared to control individuals. Therefore, 
the present analysis of cortical thickness aims to determine whether the GM volume 
reduction by VBM is due to decreased cortical surface area, cortical thickness, or both.  
 
4.2.3 Hypothesis 
 
It is hypothesized that cortical thickness is significantly different between control 
and ALS patients, especially the ALS-FTD subgroup, and also within the ALS subgroups 
themselves. We also hypothesize that if significant changes in cortical thickness are 
observed between ALS patients and control subjects, then the neurodegeneration 
mechanism in the ALS subgroup may be a neuronopathy affecting the neuronal perikayon.  
 
4.2.4 Method 
 
4.2.4.1 Imaging protocol 
 
Magnetization prepared rapid gradient echo (MPRAGE) sequence was used to 
acquire T1-weighted images on a 1.5 T system (Siemens Symphony, Erlangen, Germany) 
in 11 control subjects (8 men, 3 women) and 72 ALS patients: 13 UMN-predominant 
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with CST hyperintensity (8 men, 5 women), 25 UMN-predominant without CST 
hyperintensity (16 men, 9 women), 14 typical ALS with mixed UMN and LMN signs (9 
men, 5 women) and 20 with ALS-FTD (5 men, 15 women). This high resolution 3D T1-
weighted MPRAGE sequence provided good GM-WM contrast14. MPRAGE sequences 
are less sensitive to pulsation artifacts because of shorter TEs and saturation effects of 
flowing blood in the whole excitation volume12. MPRAGE pulse sequence parameters 
were: TR = 1970 ms, TE = 4.38 ms, number of averages = 1, flip angle =10o, TI =1100 
ms and scan time = 6.45 minutes; imaging parameters were: number of slices = 160, 
contiguous, slice thickness = 1 mm, in-plane resolution = 0.9×0.9 mm.  
4.2.4.2 Data Processing 
 
Cortical thickness measures were carried out using Freesurfer, an openware 
(http://surfer.nmr.mgh.harvard.edu/). Image processing steps begin with motion 
correction and skull stripping based on hybrid watershed /surface deformation 
procedure21. The images are then registered to a Talairach brain template, segmented for 
subcortical WM and GM structures22, and intensity normalized for uniform intensity 
values across the WM and GM structures23. After intensity normalization, a tessellation 
step estimates the GM-WM boundary and subsequent automated topology correction24,25. 
The GM-WM and GM-cerebrospinal fluid (GM-CSF) boundaries are optimally placed 
using surface normalization and intensity gradients20,26. After cortical models are 
completed, deformable procedures are performed for further processing and analysis like 
surface inflation and registration to a spherical atlas27. Both intensity and continuity 
information from the entire 3D MR volume is used to produce representations of cortical 
thickness and thickness is measured as the closest distance from GM-WM to GM-CSF 
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boundary at each vertex on the tessellated surface20 as shown in figure 29 below. Because 
the maps are not restricted to voxel resolution of the original data they are capable of 
detecting submillimeter differences between groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: MPRAGE image showing how cortical thickness (arrows) is 
determined between GM-WM (broken yellow line) and GM-CSF (broken red line) 
boundaries. 
Adapted from Fischl, Tutorial slides. 
 
 
4.2.5 Results 
 
High resolution 3D T1-weighted images from all control and ALS subjects were 
processed as described in the data processing section. This analysis provides additional 
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information on the changes in GM structures, as discussed previously (i.e. volume = area 
* thickness). Cortical thickness, surface area, and volume were compared between 
control and ALS subgroups using the GLM statistical model with FDR at p< 0.05 for 
multiple comparisons. Significant differences in cortical thickness were observed only 
between control subjects and the ALS-FTD subgroup, as shown below in figure 30. 
These regions were mapped based on the Desikan28 atlas. Table V below gives the 
Talairach coordinates and corresponding cortical regions, which were significantly 
different between the control and ALS-FTD groups. No significant differences in cortical 
thickness were observed between control and any of the other ALS subgroups. Cortical 
surface area and volume were also compared between control subjects and ALS patients. 
No significant differences were observed in cortical surface area but cortical volume 
(Note that cortical volume here refers to volume of the cortex whereas in VBM study the 
volume measured has both cortical and sub cortical GM structures)  was significantly 
different between control and only ALS-FTD groups, as shown in figure 31; no 
significant differences in cortical volume were observed between control individuals and 
any other ALS subgroups. Table VI below gives Talairach coordinates of regions which 
were significantly different between control and ALS-FTD groups for both cortical 
volume and thickness metrics. Therefore, these results indicate that decreased cortical 
volume in the ALS-FTD patients (found by VBM) is due to reduced cortical thickness 
and not reduced cortical surface area.   
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Figure 30: Colored regions (heat map) indicate regions of statistical 
significance (p<0.01) superimposed on average inflated template showing cortical 
thinning in ALS-FTD patients relative to controls results are projected onto the left 
hemisphere, laterally (top left image), medially (bottom left image) and right 
hemisphere, laterally (top right image), medially (bottom right image). Color bar is 
scaled in units of log 10 (p) 
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Figure 31: Colored regions (heat map) indicate regions of statistical 
significance (p<0.01) superimposed on average inflated template showing reduction 
in cortical volume in ALS-FTD patients relative to controls results are projected 
onto the left hemisphere, laterally (top left image), medially (bottom left image) and 
right hemisphere, laterally (top right image), medially (bottom right image). Color 
bar is scaled in units of log 10 (p) 
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Table V: Talairach coordinates and regions which are significantly different 
between control and ALS dementia groups using cortical thickness measure 
Talairach coordinates 
(vertex of cortical region) (X, 
Y, Z) 
Cortical regions 
significantly affected in ALS 
dementia 
-37.55, 42.61,4.82 rostral middle frontal 
-46.14, 30.35, -3.23 lateral orbitofrontal 
-40.43, 38.91, -12.20  pars orbitalis 
-32.81, 21.55, -17.09 lateral orbitofrontal 
-50.36, 15.76, 16.36 pars opercularis 
-34.99, 9.32, 31.24 caudal middle frontal 
-50.57, 3.39, 27.25 precentral gyrus 
-59.25, -15.11, 17.06 postcentral gyrus 
-20.47, 23.90, 39.84 superior frontal 
-33.22, 1.29, 5.70 insula 
-50.74, -0.23, -9.71 superior temporal 
-58.22, -10.57, -18.96 middle temporal 
-53.69, -26.93, -21.94 inferior temporal 
-54.28, -34.79, 31.34 supramarginal 
-35.83, -42.63, 50.00 superior parietal 
-42.60, -50.87, 22.47 inferior parietal 
-53.93, -43.88, 0.51 banks of superior 
temporal sulcus 
-47.48, -19.26 , 6.55 transverse temporal 
-42.24, -77.29, 4.81 lateral occipital 
-10.45, 47.28, 13.50 superior frontal 
-5.41, -10.39, 35.99 posterior cingulate 
-8.41, -31.26, 27.05 isthmus cingulate 
-6.69, -57.13, 17.09 precuneus 
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-12.61, -77.93, 14.91 pericalcarine 
-4.18, -75.36, 23.06 cuneus 
-12.73, -23.40, 45.41 paracentral 
-7.84, 40.16, -0.64 rostral anterior cingulate 
-28.52, -5.33, -28.31 entorhinal 
-27.18, -49.98, -11.27 fusiform 
-25.83, -48.36, -2.05 lingual 
-26.83, -40.03, -6.55 parahippocampal 
-7.47, 16.15, -15.29 medial orbitofrontal 
-9.10, 21.47, 25.17 caudal anterior cingulate 
 
 
Table VI: Talairach coordinates and regions which are significantly different 
between control and ALS-FTD groups in both cortical thickness and in cortical 
volume (right side) 
 
Talairach coordinates 
(vertex of cortical region) (X, 
Y, Z) 
Cortical regions 
significantly affected in ALS 
dementia 
-50.36, 15.76, 16.36 pars opercularis 
-37.55, 42.61,4.82 rostral middle frontal 
-34.99, 9.32, 31.24 caudal middle frontal 
-50.57, 3.39, 27.25 precentral gyrus 
-54.28, -34.79, 31.34 supramarginal 
-59.25, -15.11, 17.06 postcentral gyrus 
-35.83, -42.63, 50.00 superior parietal 
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-42.60, -50.87, 22.47 inferior parietal 
-42.24, -77.29, 4.81 lateral occipital 
-58.22, -10.57, -18.96 middle temporal 
-53.93, -43.88, 0.51 banks superior 
temporal sulcus 
-50.74, -0.23, -9.71 superior temporal 
-33.22, 1.29, 5.70 insula 
-32.81, 21.55, -17.09 lateral orbitofrontal 
-40.43, 38.91, -12.20  pars orbitalis 
-20.47, 23.90, 39.84 superior frontal 
-7.47, 16.15, -15.29 medial orbitofrontal 
-7.84, 40.16, -0.64 rostral anterior 
cingulate 
-9.10, 21.47, 25.17 caudal anterior 
cingulate 
-12.73, -23.40, 45.41 paracentral 
-5.41, -10.39, 35.99 posterior cingulate 
-8.41, -31.26, 27.05 isthmus cingulate 
-6.69, -57.13, 17.09 precuneus 
-25.83, -48.36, -2.05 lingual 
-28.52, -5.33, -28.31 entorhinal 
 
4.2.6 Discussion 
 
We have found that cortical thickness and cortical volume are reduced not only in 
motor regions but also in non-motor frontal and temporal areas of ALS-FTD patients 
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compared to control subjects, as described above. Frontal and temporal lobes are mainly 
responsible for cognitive functions, including memory, object identification, facial 
recognition. Absence of significant differences between control subjects and other (non-
demented) ALS patients suggests a subcortical axonal and not primarily perikaryal 
neurodegenerative process in the latter patients. Therefore, the significant reductions in 
cortical volume and thickness we identified in ALS-FTD patients support our hypothesis 
that primary neurodegeneration in these patients occurs in the perikaryon, as a 
neuronopathy. Little has been studied regarding cortical thickness in ALS patients. To our 
knowledge, only one study by Roccatagliata and colleagues (also using Freesurfer)18 
compared cortical thickness in 14 ALS patients and 12 control subjects over 3 regions of 
interest: precentral, postcentral and lateral occipital cortices. Cortical thickness was 
significantly reduced only in the precentral region and no correlations were observed 
between cortical thickness and clinical scores. Our study, on the other hand, found 
significant reductions in cortical thickness in precentral, postcentral (included both gyri 
and sulci) and lateral occipital cortices only in ALS-FTD patients, but not in ALS patients 
without dementia (i.e., in the other subgroups). It is difficult to determine the reason for 
the discrepant results between the two studies because we classified our patients based on 
the presence of prominent UMN signs, CST hyperintensities, or FTD, whereas  the ALS 
patients of Roccatagliata et al examined ALS patients with a combination of UMN and 
LMN signs and either bulbar or spinal onset but no dementia18 Nonethess, discrepancies 
in results of published VBM ALS studies arises when patients with differing clinical 
signs are included in the same group5,7,14, as was the case in the study by Roccatagliata 
and colleagues18. Significant cortical thinning only in ALS-FTD patients and not in any 
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of the other ALS subgroups further emphasizes the need to categorize ALS patients based 
on their clinical phenotype. This will likely lead us to a better understanding of different 
pathophysiological mechanisms involved in ALS.   
Use of cortical thickness analysis to identify significant decreases in cortical 
thickness and volume in ALS-FTD patients demonstrates the additional 
perspective/dimension obtained compared to VBM analysis. Cortical thickness analysis 
revealed that volume reduction (also seen by VBM) is due to decreased thickness and not 
by changes in cortical surface area. However, cortical surface area reductions have been 
observed in normal aging29 and in Alzheimer’s disease15.  However, visual comparison of 
figures 30 and 31 shows more cortical regions showing thinning (30) than atrophy (31). 
Although the reason for this is unclear, one possibility is that cortical thinning may be a 
more sensitive change than obvious volume decrease (atrophy); since cortical area is 
unchanged, it may be masking cortical volume changes (since volume =thickness*area).  
 
4.2.7 Conclusion 
 
Our results clearly demonstrate that the decreased cortical volume (by VBM) is due 
to reduced cortical thickness and that this occurs in patients with ALS-FTD. This 
suggests primary pathology occurring at the cortical neuron cell body (perikaryon) as a 
neuronopathy in this ALS subgroup. Such cortical thinning occurs only in ALS-FTD 
patients but not in the other ALS patient subgroups in which neurodegeneration may be 
primarily subcortical, affecting axons as a “dying back” process. Our findings suggest 
differences in the underlying neurodegenerative processes in these subgroups of ALS 
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patients, and support the need for subclassification of patients based on clinical 
phenotype in further ALS research. 
 
4.2.8 Limitations and Future scope 
 
The major limitations of this study were the small control group size and the need 
for manual intervention to edit out non-brain regions not removed during the automated 
brain extraction step, and possibly introducing some operator bias. The latter possibility 
can be assessed by measuring intra-operator reliability in the future. 
Results obtained from cortical thickness analysis can be combined with DTI metrics to 
evaluate the contribution of cortical degeneration (neuronopathy) and subcortical 
degeneration (axonopathy) in each of the ALS patient subgroups. A correlation map can 
be obtained between reductions of cortical thickness and cortical volume to better 
understand the relative interaction of these two measures. It would be worthwhile 
examining other cortical measures such as average convexity (which measures the 
depth/height of each point above an average surface), smoothed mean curvature and 
Jacobian matrix (amount of anatomical variability between subjects). These parameters 
may provide more information about the forms and complexity of cortical degeneration 
in ALS.  
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CHAPTER V 
CONCLUSION 
 
 
 
The etiology and site of origin of ALS are unknown. Neurodegeneration can 
begin either in the upper motor neuron (UMN) or lower motor neuron (LMN), and even 
within an UMN origin, neurodegeneration can be an axonopathy or a neuronopathy. 
Based on preliminary data we hypothesize that ALS is predominantly an axonopathy, but, 
in ALS patients with frontotemporal dementia (FTD), it is neuronopathy. We also 
hypothesize that onset of neurodegeneration in patients with typical ALS is more caudal 
along the corticospinal tract (CST) when compared with UMN-predominant ALS.Axonal 
integrity will be investigated using T2 relaxometry and DTI, while neuronal integrity will 
be assessed by quantitative methods of voxel-based morphometry (VBM) and cortical 
thickness on qualitative T1-weighted images. 
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Study 1 
Many clinical studies employ dual echo fast spin echo (FSE) sequence for 
measuring T2 relaxation times, although this is prone to high spatial frequency effects 
depending on the brain region of interest. Therefore in this study we evaluated the 
accuracy of T2 relaxation time measurements from dual echo FSE sequence relative to 
more robust multiple echo spin echo (SE) sequence prior to employing the former to 
evaluate pathologic changes in ALS. The results showed large systematic errors when 
using dual echo FSE sequence relative to multiple echo SE sequence. Therefore, we 
conclude that future T2 relaxometry studies employ multi-echo SE sequence or CPMG 
sequence for accurate and reliable results. 
 
Study 2 
Axonal integrity in ALS patients was evaluated using scalar DTI metrics. We also 
explored the usefulness of radial and axial diffusivities, Westin’s linear and planar indices 
which are yet to be studied in ALS. We believed that axial and radial diffusivities, 
Westin’s linear and planar indices provide additional information about 
pathophysiological changes in ALS when compared to the commonly used metrics of FA 
and MD.  
1) All diffusion tensor metrics from DTI showed significant differences between ALS 
patients compared to control sunjects. Notably, subgroup of classic ALS patients 
showed abnormalities at more caudal levels of CST, supporting our hypothesis that 
site of maximal neurodegeneration (and possibly origin) in these patients is more 
caudal than in the UMN-predominant ALS subgroup. 
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2) Absence of significant differences in any DTI metrics of CST hyperintense and CST 
non hyperintense ALS groups, supporting our hypothesis that divergent pathologies 
occur in the subcortical axons (e.g. spinal cord). 
3) Axial and radial diffusivities provided novel information about pathophysiology of 
ALS in that they showed not only significant differences between ALS subgroups but 
also showed significant difference at more rostral levels of CST which were not 
observed with FA metrics. Westin’s linear and planar indices identified fiber crossings 
which were otherwise not distinguished with FA.  
In general DTI metrics revealed group specific differences which clearly supported 
our view that better insight into the pathophysiological mechanisms of ALS will be 
obtained by categorizing ALS patients into subgroups based on clinical phenotypes. 
Study 3 
Neuronal integrity in grey matter structures was evaluated by measuring changes 
in grey matter volume, using voxel-based morphometry (VBM) method, and cortical 
thickness in ALS patients and control subjects. Since volume change could result from 
changes in cortical thickness, cortical surface area, or both, cortical thickness 
measurements were employed to investigate this. Both VBM and cortical thickness 
results showed significant reduction in grey matter volume (by VBM) and thinning of 
cerebral cortex occurred only in ALS dementia group when compared to controls. This 
supported our hypothesis of early perikaryal degeneration  (neuronopathy) in this ALS 
subgroup and resultant global anterograde wallerian degeneration.  Absence of significant 
reductions in cortical volume and thickness in other ALS patient subgroups supports our 
hypothesis that neuronal degeneration in these patients is primarily an axonopathy. Lack 
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of cortical surface area reductions clearly demonstrates that volume changes found by 
VBM are due to decreased cortical thickness and not cortical surface area. This provides 
additional insight into pathological changes in ALS brain. 
 To our knowledge, this is the first clinical study in ALS with a sufficiently large 
sample size that allows subcategorizing of ALS patients by clinical features to reveal 
subgroup specific differences in brain pathology using DTI metrics, VBM and cortical 
thickness measures. These findings suggest that ALS pathogenesis is variable among 
patients and support the notion that ALS is not a single disease but rather a syndrome.  
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APPENDIX 
 
Histograms of T2 relaxation error values along CST and in whole brain  grey 
matter (GM) and white matter (WM) structures in all 8 subjects under study (Chapter 2) 
Subject 1 
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